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Tuberculosis (TB) has emerged as the world’s most deleterious infectious disease. The etiological agent of 
TB, Mycobacterium tuberculosis (Mtb), has evolved the ability to evade the host immune system using 
several mechanisms; emphasising the need for novel treatment strategies. Peptidoglycan (PG) is an 
important immunomodulatory heteropolysaccharide structure that can be shed during mycobacterial 
infection with immunological consequences and as such, changes in PG structure are expected to have 
important implications on disease progression and host responses. Mycobacterial amidases have been 
shown to have important roles in the remodelling of PG during cell division in M. smegmatis and are 
implicated in sensitivity to antibiotic treatment. However, their roles in modulating host immunity remain 
unknown. Herein, we assess the immune responses to Mtb mutants defective for either one of two 
amidases, Ami1 and Ami4, in bone marrow-derived macrophages (BMDM) and the C57BL/6 murine 
models of tuberculosis. Both Ami1 and Ami4 deletion resulted in increased pro-inflammatory response in 
BMDM. Infection with the Mtb Δami1 mutant in mice resulted in differential induction of pro-
inflammatory cytokines and certain chemokines during the acute phase of the infection, an eff ect that 
was abrogated in chronic phase infection. The Δami1 mutant was found to be susceptible to antibiotics in 
liquid growth culture but this sensitivity was negated in macrophages and reversed to a tolerant 
phenotype in mice. The Δami4 mutant, by contrast, did not display differential antibiotic susceptibility 
and did not significantly alter cytokine and chemokine responses relative to the wildtype control in mice. 
These findings suggest that Ami1 and Ami4 in Mtb play a nonoverlapping role in antibiotic sensitivity and 
modulating host immunity during tuberculosis.  
Additionally, the specific epigenetic alterations which occur during host-Mtb infection that contribute to 
immune evasion remain unknown. Here, we propose a method to elucidate transcriptomic changes in 
both human primary monocyte-derived macrophages (MDM) and the Mtb bacillus with which they were 
infected. In this study, we exhibit a dual-RNA-seq proof-of-concept methodology where, from a single 
donor, we successfully sequence host RNA from infected MDMs as well as Mtb RNA enriched from those 
same infected MDMs. Utilizing this optimised methodology, we aim to discover and model epigenetic and 
transcriptional alterations as well as their effector proteins in primary human macrophages following Mtb 
infection. Further, we aim to identify novel and annotated ncRNAs which are correlated with these 






1 Chapter One 
Literature Review 
 
1.1 Tuberculosis History and Discovery 
Tuberculosis (TB) is an ancient disease which has afflicted sensitive human populations worldwide for 
thousands of years [1]. Modern molecular biological and sequencing techniques have implied that 
Mycobacterium tuberculosis (Mtb) was found in East Africa approximately three million years ago [2]. 
However, it is understood that the modern Mtb strains which affect the world today may have arisen 
only 20000 – 15000 years ago [3, 4]. Further, the six strains, or lineages, which are currently present 
in the human population worldwide are all present in East Africa today [5]. These lines of evidence 
imply that the establishment of humanity may have coincided with the occurrence and spread of TB 
from Africa to the rest of the world. In addition to the direct evidence of TB presence in ancient East 
Africans, TB has also been observed in Egyptian remains and art as long as ~5000 years ago [6-8]. 
Additional lines of evidence have shown that as humans spread out of Africa, TB was spread as far as 
China, India, Peru and the Americas [7].  
Perhaps more famous, was the first documented identification of TB in Ancient Greece by Hippocrates. 
The disorder which then known by the Greeks as phthisis.  Hippocrates understood TB and its clinical 
presentation. Further, he recognised and noted that phthisis primarily affected young adults [9]. 
Through the proceeding years, TB lurked within the human population claiming many victims and 
gained other names such as consumption, scrofula, the White Plague, the King's Evil and perhaps the 
most poetic; The Captain of all these Men of Death. Benjamin Marten was perhaps the first person to 
elude to the infectious nature of TB in his paper entitled “A new theory of Consumption” [10]. 
However, in 1865, a French physician named Jean-Antoine Villemin provided the first evidence of the 
infectious ability of TB by transferring infected liquid acquired from the diseased lungs of dead TB 
patients during an autopsy to a small rabbit [11]. Upon sacrificing the animal, he discovered that it 
was indeed infected with Mtb. Perhaps the greatest change in the way physicians and scientists 
understood TB was brought forward by Robert Koch [12]. In 1882, Koch presented his data to the 
Berlin Physiological Society providing evidence of the TB bacillus as well as detailing his famous 
postulates, which would later become the golden standard for the identification of infectious agents 
worldwide. Later in 1890, Koch presented his work on a compound that he had isolated from Mtb 
[13]. He claimed that this substance, tuberculin, could remove TB bacilli from a human body and thus 
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be the first anti-TB therapeutic to protect against TB. Ultimately, tuberculin was proved to be 
ineffectual against TB, however, Koch claimed that the substance may have a role in diagnostics in the 
future. Roberts Koch’s contribution toward the field of infectious bacteriology, particularly his work 
on the aetiology of TB, later earned him the 1905 Nobel Prize in Medicine and Physiology. Additional 
knowledge of TB was later added by Clemens Freiherr von Pirquet in 1909. In that year, Pirquet 
published a detailed study providing evidence in which he showed that children which were exposed 
to tuberculin exhibited a localised immune response similar to that of active TB patients, but never 
progressed to TB themselves; these children he termed ‘latently infected’ – a term which is still in use 
and actively debated today [14]. The next tool in the war against TB was discovered in the 1930s where 
Florence Seibert developed a standardised purified protein derivative, or PPD, which provided a 
comparable method to better carry out the tuberculin skin test and elucidate the epidemiology and 
biology of TB at that time [15]. Despite the growing understanding of TB aetiology and pathogenesis, 
the disease still had a deleterious impact worldwide.  
Improvements in diagnostics such as X-ray identification of lesions helped in the diagnosis of the 
disease, however, the treatment of TB consisted primarily of a healthy diet and ample sunshine; a 
treatment regime that was used in almost all sanitoria worldwide. However, a powerful weapon 
against TB was discovered in 1921 by Albert Calmette and his partner Camille Guerin who were 
working on a vaccine for TB at the Pasteur Institute of Lille where they strived to attenuate 
Mycobacterium bovis. This attenuated mycobacterium vaccine, called BCG, was to be the first and 
only commercially available vaccine to TB for almost the next 100 years [16]. The protective effect of 
BCG was first observed in an infant whose mother was TB positive and was given into the care of TB 
positive grandmother – miraculously, the child did not develop TB. In 1944, the next landmark victory 
against TB was made by Albert Schatz, Elizabeth Bugie, and Selman Waksman. Those authors first 
reported on an antibiotic compound named streptomycin which had anti-Mtb activity and was 
clinically verified soon after [17, 18]. Ten years later, the discovery of efficacious oral anti-TB drugs; 
primarily, isoniazid and rifampicin in 1952 and 1957 respectively, was the turning point in the fight 





Figure 1: TB Timeline and Implementation of Treatment Strategy 
 
1.2 Tuberculosis: A Modern-Day Global Health Crisis 
Improvements in TB education, healthcare and drug-development have served to drastically reduce 
the incidence and mortality observed since the mid-19th century, where 1 in 4 people was killed by TB 
in America and Europe [20]. However, factors such as the emergence of HIV in the early 1970s, the 
global increase of other immunosuppressive diseases and the increasing incidence of drug-tolerant 
phenotypes have powered the modern-day spread TB [21]. It is estimated that approximately 1 in 4 
people are latently infected with Mtb, the etiological agent of TB [21]. However, of this large 
proportion, only 10% will progress to the active disease within their lifetime [21, 22]. The loss of host-
directed immune control of Mtb is a prerequisite for reactivation of latent infection or progression to 
TB [23]. It is well documented that immunosuppressive states such as HIV infection, diabetes, 
malnutrition, extreme age (both very young and very old) and tumour necrosis factor (TNF) therapies 
all contribute to the loss of mycobacterial control [22-24]. Further, TB may present as a spectrum of 
disease ranging from latent TB infection (LTBI), characterised by the presence of un-transmissible, 
quiescent Mtb within the host without the clinical symptoms, to active TB infection (ATBI). ATBI is 
characterised by abnormal chest x-rays, sputum positive cultures, coughing, chest pain, weight loss, 
anaemia and night sweats. The exact cellular mechanisms and factors which lead to disease 
pathogenesis in these physiological sensitive states, and what contributes to latent vs. active disease, 
are still poorly understood.  
The disease’s mode of transmission has played a key role in the successful dissemination of TB on a 
worldwide scale. The bacillus is transmitted within aerosolized droplets from a TB-infected patient’s 
cough or sneeze. This implies that uninfected individuals are at risk of being exposed to the pathogen, 
and potentially become infected, simply via breathing. During 2018, there were approximately 10 
million documented new cases of TB worldwide with 57% occurring in men, 32% occurring in women 
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and 8.6% occurring in children respectively [21]. It is reasonable to assume that these figures are 
underestimating the true distribution of disease due to poor diagnostic capabilities and healthcare 
infrastructure in countries where the prevalence of the disease is highest. In terms of disease 
incidence, most of the burden is experienced by the regions of Sub-Saharan Africa and South-east Asia 
(Fig. 2), with eight countries; South Africa, China, Pakistan, India, Nigeria, the Philippines, Bangladesh 
and Indonesia being accountable for up to approximately 60% of global disease burden [21]. 
 
 
Figure 2: Estimated TB incidence in 2018, for countries with at least 100 000 incident cases. The 
global burden of TB is localised to the Sub-Saharan African and South-East Asian Regions. Adapted 
from the World Health Organisation Global TB Report, 2019 [21].  
 
TB has become the world’s highest infectious killer and is the main cause of mortality in HIV -infected 
individuals [21]. In high burden countries such as South Africa, the percentage of new and relapse 
cases of TB can be upwards of 50% in individuals who are HIV positive  [21]. Though HIV-infected 
individuals are at a notably higher risk for contracting TB, the large majority (± 70%) of deaths due to 
TB occur in HIV-negative individuals (Fig. 3 and 4). In 2018, 1.2 million deaths due to TB were observed 
in HIV-negative patients relative to 250 000 deaths attributed to HIV-TB coinfection. These mortality 




Figure 3: Approximate HIV prevalence observed in new and reactivation cases of TB, 2018. In high 
burden countries, such as South Africa, upwards of 50% of new and reactivation TB cases occur in HIV-
positive patients. Adapted from the World Health Organisation Global TB Report, 2019  [21].  
 
 
Figure 4: Estimated deaths due to TB in HIV-negative individuals, 2018. The global mortality of TB is 
localised to the Sub-Saharan African and South-East Asian Regions. Adapted from the World Health 




The long duration of treatment (and associated poor adhesion to treatment regimens), improper 
dosing of antibiotic treatments and/or interrupted drug logistics in countries with poorly developed 
health infrastructure has led to the advent and increased spread of drug-resistant strains of Mtb (Fig. 
5). These strains have far-reaching deleterious implications, particularly for immunocompromised 
individuals who are already at risk of TB, as well as “healthy” persons in high -burden third-world 
countries.  
The generation and spread of treatment-resistant phenotypes of Mtb, perhaps unsurprisingly, mirrors 
the burden of global TB as seen in Figure 1. In 2018, it is estimated that approximately 500 000 new 
cases of TB (~5%) exhibited rifampicin (RIF) resistance, of which, 78% were multiple drug-resistant 
(MDR). The highest observed incidence of treatment-resistant TB originated in India (27%), China 
(14%) and the Russian Federation (9%) (Fig. 5). 
 
 
Figure 5: Estimated incidence of drug-resistant TB in 2018. Adapted from the World Health 
Organisation Global TB Report, 2019  [21] 
 
1.3 The Lifecycle of Mtb: Infection, Immunopathology and Treatment 
Mtb is a slow-growing, aerobic bacterium which historically only affects human hosts, and is not found 
in other species or abiotic environments [25]. The causative infectious unit of TB, Mtb, is transmitted 
as an aerosol within microscopic droplets when an infected individual with active disease coughs, 
sneezes or speaks (Fig. 6). In high burden countries, this imposes a significant problem for a high 
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proportion of the population, who live in high density, low-income areas and will experience an 
increased risk of exposure simply via breathing. In 90% of infected individuals, the host immune 
response can effectively control infection and prevent progression to disease. Infected individuals, 
where this control is evident, are termed latently infected and are unable to spread the pathogen to 
uninfected persons. The factors which facilitate eradication or lifelong control in latently infected 
individuals remains unclear. Conversely, in 10% of individuals, the adaptive immune phase fails to 
control Mtb infection. This loss of control ultimately leads to the reactivation of disease in people who 
have been previously infected, as well as facilitates the dissemination and progression to disease in 
new cases of infection. Again, the exact mechanisms which contribute to this loss of control are still 
largely unknown, however extreme age, as well as diseases and treatments which induce suppression 
of the host immune system, are hypothesised to play key roles. Progression to active disease results 
in the presentation of multiple symptoms such as chronic coughing, weight loss, fever, night sweats, 
blood in sputum, chills and a loss of appetite [21].  
 




During the initial infection, the Mtb bacillus is detected and phagocytosed by tissue-resident alveolar 
macrophages within the lung parenchyma [27]. These tissue-resident cells, the first line of defence 
against infection, then release several cytokines (TNFα, IFN-y) and chemokines to initiate a 
coordinated immune response comprising of different cellular subtypes (Fig. 6). Neutrophils followed 
by peripheral monocytes which differentiate to interstitial macrophages are recruited quickly to the 
initial site of infection[27]. Later, dendritic cells, another subset of professional antigen-presenting 
cells (APC), are recruited to the site of infection and, via efferocytosis, take up dead or dying immune 
cells, live bacilli and bacterial antigen [28, 29]. These cells then translocate into the lymphatic system, 
eventually finding their way to the lymph nodes and initiating the humoral/adaptive  immune 
response. This translocation of DCs is coordinated via IL-12p40 and the chemokine receptors CCR2 
and CCR7 [30]. In the draining lymph nodes from the lung, the infected DCs stimulate the CD4+ T cells 
via MHCII resulting in the differentiation and the clonal expansion of TH1 type CD4+ T Cells [31]. These 
cells primarily express and secrete high levels of interleukin 2 (IL-2) and interferon-gamma (IFN-y) [32]. 
The expression of CXCR5 on these Th1 cells allows them to locate themselves efficiently around the 
granuloma through the interaction of IL-23 and CXCL13 [33, 34]. These TH1 cells, and the IFN-y and 
TNFα that they secrete, are essential for a successful immune response and formation/maintenance 
of the granuloma [35]. Both mice and human patients which are deficient in IFN-y are extremely 
sensitive to Mtb infection, have defective granuloma formation, heightened neutrophil recruitment, 
increased inflammation and necrosis [36-38]. Further, the cellular differentiation of CD4+ T-cells to TH1 
cells is dependent on the transcription factor T-bet [39]. Mice deficient in T-bet have been observed 
to have diminished CD4+ T cell IFN-y responses, a high infiltration of eosinophilic macrophages, giant 
cells and neutrophils, and are ultimately more susceptible to Mtb infection [40]. Whilst the presence 
of TH1 cells is essential to mounting an effective immune response to Mtb, the cytokine environment 
in which they differentiate is equally important. Previous studies have found IL-12 and IL-23 are critical 
to mounting efficient IFN-y T cell responses during mycobacterial infection [34, 41]. However, patients 
with mutations in these genes were still able to form granulomas, indicating that while IL-12 and IL-
23 are important in Mtb infection they are not as indispensable as IFN-y. DCs are the main source of 
both cytokines, providing a positive feedback loop between Th1 cells and themselves, which is 
ultimately regulated by endogenous IL-10 [42].  
Whilst the uptake of Mtb bacilli is reasonably efficient, it is evident from the exponential growth of 
intracellular Mtb that macrophages alone are insufficient to control TB pathogenesis [43, 44]. This 
situation is changed somewhat upon the arrival of the adaptive immune response (B- and T-cells) 
which activates and amplifies the ability of macrophages to control Mtb growth. IFN-y induced killing 
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is achieved through the secretion of ROS and inducible nitric oxide synthase [45]. The coordinated 
action of the innate and adaptive immune responses facilitates the formation of a mature granuloma; 
consisting of an inner section of macrophages and neutrophils which is surrounded by fibrotic tissue, 
fibroblasts, epithelial macrophages and other lymphocytes. The formation of lung granulomas is a 
hallmark of clinical disease and vital for the control of Mtb proliferation and infection. However, when 
immune control fails, granulomas are also the biological reservoir that initiates new infections from 
the original host. Further, certain immune cells within the granuloma are permissive to Mtb. Foamy 
macrophages are another common immune cell subset. Their “foamy” morphology is a consequence 
of a large accumulation of intracellular lipid droplets [46]. Further, phagolysosomal maturation is 
abrogated in these macrophages due to their general M2 phenotype. The slow maturation of the 
phagolysosome coupled with the ability of phagocytosed Mtb to utilise the lipid droplets as a carbon 
source has allowed Mtb to reside within these macrophages, creating a reservoir of infection [27, 46]. 
Multinucleated macrophages, formed via the fusion of multiple individual macrophages and the 
activation via Mtb-derived lipomannan, are another cellular subset which is thought to be permissive 
to Mtb pathogenesis [47]. It has been shown that these cells have a diminished ability to phagocytose 
Mtb bacilli but an increased ability to phagocytose apoptotic macrophages [47].   
An acellular, creamy, cheese-like substance named caseum is often observed to form at the centre of 
many granulomas. This caseum is comprised of necrotic tissue, dead immune ce lls and viable, 
proliferating bacilli (Fig. 6) [48]. If the formation of the host granuloma and subsequent immune 
response is successful, the continued formation of the caseum is abrogated, with the necrotic tissue 
becoming progressively calcified and fibrotic. Such granulomas are considered the clinical hallmarks 
of a successful host immune response. However, should the immune response be unsuccessful, the 
caseum increases in size and becomes progressively more liquid over time. Further, the liquid caseum 
is laden with billions of viable, amplifying Mtb bacilli which, upon the physical breakdown of the 
granuloma, are released into the lung cavity. This phenomenon results in the cavitation of host lung 
tissue and allows for the spread of Mtb to new, uninfected hosts [48]. 
1.3.1 Treatment of Tuberculosis 
Without treatment, TB is often fatal and can disseminate to other parts of the body apart from the 
lungs, such as the kidneys, spine, meninges or joints which can cause significant deleterious effects in 
peripheral parts of the body [49]. Fortunately, TB is readily curable with the duration of treatment 
lasting approximately six to nine months. 
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Table 1: Anti-TB Medication throughout the years. Adapted from Marimani et al., 2018 [50] 
1st/2nd Line 
Treatment 
Anti-TB Drugs Discovered 
Anti-TB 
Action 
Mode of Action 
2nd Line Amikacin 
(AMK) 
1972 Interacts with the 30S ribosomal subunit 
inhibiting protein synthesis 
 Bedaquiline 2012 Inhibits energy production by halting the 
activity of ATP synthase 
2nd Line Capreomycin 
(CAP) 
1963 Associates with the 70S ribosomal subunit 
and prevents protein synthesis 
 Clofazimine 1950 Binds to Mtb DNA leading to growth 
retardation 
2nd Line Cycloserine/ Terizidone 
(Cs /Trd)  
1955 Impairs cell wall synthesis and diminishing 
growth by changing the role of D-alanine in 
the Mtb cell wall 
1st Line Ethambutol 
(EMB) 
1961 Impairs metabolism and induces cell death by 
preventing synthesis of required metabolites  
2nd Line Ethionamide 
(ETH) 
1961 Disrupts Mtb cell wall biosynthesis by 
inhibiting the production of mycolic acid 
1st Line Isoniazid  
(INH) 
1952 Disrupts Mtb cell wall biosynthesis by 
inhibiting the production of mycolic acid 
2nd Line Levofloxacin 
(LVX) 
1992 Disrupts DNA replication, transcription, 
recombination and repair by blocking the 
activity of DNA gyrase and topoisomerase IV  
 Meropenem 1976 Induces cell death by inhibiting the synthesis 
of vital cell wall components 
2nd Line Moxifloxacin 
(MXF) 
1988 Inhibits DNA replication and transcription via 
the association with the subunit of DNA 
gyrase  
2nd Line Ofloxacin 
(OFX) 
1980 Inhibits of DNA replication, transcription, 
repair and recombination bacterial via the 
association to topoisomerase IV and DNA 
gyrase 
2nd Line p-aminosalicylic acid 
(PAS) 
1948 Diminishes bacterial growth and depleted 
iron by the impairment of the synthesis of 
folic acid and mycobactin, respectively  
1st Line Pyrazinamide 
(PZA) 
1954 Prevents translation by associating with the 
ribosomal protein S1 (RpsA) and diminishes 
fatty acid synthesis 
2nd Line Prothionamide 
(Pto) 
1965 Disrupts Mtb cell wall biosynthesis by 
inhibiting the production of mycolic acid 
1st Line Rifabutin 
(RBT) 
1975 Prevents chain initiation via the impairment 
of RNA polymerase 
1st Line Rifampicin 
(RIF) 
1963 Prevents chain initiation via the impairment 
of RNA polymerase 
1st Line  Rifapentine 
(RPT) 
1965 Prevents chain initiation via the impairment 
of RNA polymerase 
2nd Line Streptomycin 
(STR) 
1944 Inhibits protein synthesis via the association 
to the 30S ribosomal subunit 
2nd Line Kanamycin 
(KAN) 
1957 Interferes with the protein synthesis by 





Treatment is generally segregated into two groups: first-line and second-line drugs. First-line 
treatment is generally implemented for new cases of TB and includes Isoniazid (H/Inh), Rifampicin 
(R/Rif), Pyrazinamide (Z/Pza), Ethambutol (E/Emb) and Streptomycin (S/Stm). The second-line drugs 
are utilized for patients who have repeat infections, or those who are not responding to first-line 
treatment. It is difficult to pinpoint the exact causes which contribute toward the generation and 
spread of antibiotic-resistant strains of Mtb. However, poor adherence to treatment regimens, as well 
as improper prescription of antibiotics (incorrect regime) by doctors and clinics are widely accepted 
to be two of the major factors which have facilitated the selection and spread of drug-resistant strains 
of Mtb. 
1.4 The Successes and Failures of Modern TB Vaccine Design 
A universally efficacious vaccine or therapeutic intervention which is applicable and effective to all age 
groups is urgently needed to prevent and control TB. Efforts to develop such a therapeutic 
intervention or vaccine have been hampered primarily by a limited understanding of the mechanisms 
of protective immunity against Mtb and the mechanics of host immune invasion via the bacterium. 
The Bacillus Calmette-Guerin (BCG) vaccine has been used for almost a hundred years, with 
vaccination being dispensed in early childhood in many countries (Fig. 7 and 8) [51, 52]. The vaccine 
has been shown to confer varying efficacies of protection against disseminated disease in children and 
infants, however, BCG immunisation is unable to elicit protection to the pulmonary chronic form of 
the disease as the child progresses to adulthood [52]. 
 
Figure 7: Bacillus Calmette-Guerin (BCG) vaccination policy by country, 2015. With the exception of 
the United States of America, most countries have/had some form of BCG vaccination program 






Figure 8: Coverage of Bacillus Calmette-Guerin (BCG) vaccination, 2015. Adapted from the World 
Health Organisation Global TB Report, 2016  [51] 
 
The first new vaccine candidate since the discovery and implementation of BCG in many parts of the 
world almost 90-years-ago was an inoculant called MVA85A [53, 54]. The vaccine candidate was 
synthesised from a strain of Vaccinia Ankara virus which expressed antigen 85A from Mtb. Research 
on this vaccine candidate before clinical trials was promising, and MVA85A proceeded to clinical trials 
in both adults and infants. The vaccine was designed to be a booster following vaccination of BCG and 
was shown to have good immunogenicity in animal studies but was ultimately found to be 
unprotective in adults and infants regardless of satisfactory cell-mediated host immune responses 




Figure 9: Incidence of TB acquisition in adults receiving the MVA85A vaccine relative to those who 
received a placebo. No significant difference was observed between those patients who received the 
vaccine and the placebo group. Adapted from Ndiaye et al., 2015 [53] 
 
 
Figure 10: Incidence of TB Acquisition in Infants receiving the MVA85A vaccine relative to those who 
received a placebo. No significant difference was observed between those patients who received the 
vaccine and the placebo group. Adapted from Tameris et al., 2013 [54] 
More recently, a large scale, multinational phase 2b clinical trial has provided evidence that a novel 
adjuvanted subunit vaccine (M72/AS01E) can protect around 50% of adult individuals from 
contracting TB (Fig. 11) [55]. Whilst this is a promising step forward, the failure to create a universally 
efficacious vaccine highlights the need for new effective therapies to elicit clearance of Mtb pathogen.   
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The discovery and characterization of novel gene targets for therapeutic intervention thus remain a 
key area of TB research which holds significant promise for the alleviation of TB.  
 
Figure 11: Kaplan–Meier Estimate showing the effectiveness of the novel M72/ASO1E vaccine 
candidate. The vaccine as shown to confer protection in approximately 50% of cases. Adapted from 
Tait et al., 2019 [55]. 
 
1.5 Antibiotic tolerance/resistance in Mycobacterium tuberculosis 
As mentioned above, the occurrence of MDR- and XDR-TB are important global health issues. Drug 
resistance was first observed almost immediately after the introduction of the first TB drug, 
streptomycin [56]. Combination treatments largely solved this issue until resistant strains were 
observed utilising even these treatment strategies. It is now understood that the emergence of drug-
resistant TB can be attributed to two phenomena. Firstly,  chaotic treatment which refers to the lack 
of standardised TB treatment protocols, variations in the access to diagnosis and treatment, as well 
as socio-economic issues, contributed to the rise of these resistant strains [57]. Secondly, once drug 
resistance is observed or there are drug-resistant Mtb colonies present, the short-course 
chemotherapy strategies, namely, the “directly observed treatment, short-course” or DOTS, 
paradoxically exacerbated the emergence of drug-resistant phenotypes by providing sufficient drug 
pressure to rapidly evolve resistance to first- and second-line drugs [57]. But what are the mechanisms 
employed by Mtb to develop resistance to these anti-TB compounds?  
6 
 
The ability to sequence and compare Mtb genomes has allowed for a greater understanding of the 
mechanisms by which Mtb evolve drug resistance. It is now understood that Mtb possesses both 
intrinsic and acquired strategies for tolerance and resistance to antibiotic stress.  
1.5.1 Intrinsic Attributes and Mechanisms which Contribute to Antibiotic Resistance 
One of the primary aspects which hamper the ability of the antibiotic effectiveness in Mtb is the 
impermeability of its cell wall. This barrier is maintained by the complex, coordinated action of 
multiple enzymes. For example, Mur and MurB are vital enzymes involved in the biosynthesis of UDP-
N-acetylmuramic acid (UDP-MurNAC) during the formation of the peptidoglycan (PG) layer of the cell 
wall [58]. In other bacterial species, MurA can be targeted by the antibiotic Fosfomycin, however, in 
Mtb, this antibiotic does not work due to the presence of a single nucleotide polymorphism (SNP) 
where a cysteine residue, which Fosfomycin acts upon, is mutated into aspartic acid [58]. Further, Mtb 
can evade the action of β-lactam antibiotics such as amoxicillin due to the presence of a secondary set 
of Mtb-specific transpeptidases, the L, D-transpeptidases (Ldt) [59]. Mtb also possesses another 
important protein mycolyltransferase complex called antigen 85 (Ag85). These proteins facilitate the 
formation and maintenance of the bacterial cell wall [60]. Previous studies have shown that the 
inhibition of Ag85 results in an altered cell wall structure and increased permeability [61, 62]. Further, 
Mtb Ag85 gene mutants were significantly more susceptible to anti-TB compounds [63-65]. Many 
other genes have been reported to be important to Mtb cell wall homeostasis and have been 
hypothesised to be good targets for therapeutic intervention, however, this information is outside the 
scope of this dissertation and will not be discussed further.  
Mtb also possesses morphological attributes that confer significant resistance to antibiotic action. The 
Mtb plasma membrane has a significantly reduced permeability relative to other Gram-positive 
bacterial species. To overcome this, hydrophilic solutes utilise porins (transmembrane channel 
proteins) to enter the cell [66]. In M. smegmatis, MspA, a porin-like protein is responsible for the 
uptake and sensitivity of this mycobacterium to antibiotic action [67]. Further, the expression of mspA 
from M.smegmatis in Mtb was sufficient to induce sensitivity to β-lactams as well as the increased 
sensitivity to anti—TB drugs [68]. Mtb’s resistance to a large range of antibiotics is often also 
attributed to its ability to actively expel these compounds out of the cell via its efflux pumps. In Mtb, 
it has been shown that the overexpression of efflux pump proteins, such as the major facilitator 
superfamily (MFS) efflux pumps, results in an inducible drug-resistant phenotype which is clinically 
similar to MDR-TB. To illustrate that this, jefA overexpression in Mtb was shown to confer resistance 
to isoniazid and ethambutol [69]. 
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1.5.2 A Genetic Basis to Acquired Antibiotic Resistance in Mtb 
Anti-TB medications function through the specific association to a target site. Conformational changes 
that occur at these target sites can ablate the activity of the drug being used. In Mtb, the acquisition 
of point mutations or SNPs which induce drug resistance is the principal strategy by which Mtb evades 
therapeutic stress. Such mutations have been observed for all first-line anti-TB compounds. 
Resistance to INH, relative to other first-line drugs, is induced by several possible gene mutations such 
as katG, ndh, ahpC, kasA, and inhA [70]. The mechanisms of INH activity are well established. As a pro-
drug, it requires enzymatic activation by the proteins transcribed from katG. In Mtb, mutations in katG 
and the subsequent reduction in enzymatic activity, are the main sources of INH resistance [70]. 
Additionally, mutations in the promoter of the inhA gene resulting in the upregulation of inhA levels 
have been shown to confer slight INH resistance [71]. Further, previous studies looking into INH 
resistance in Mtb report that 80% of cases can be explained by a combination of these two mutations 
[72]. Mtb has also evolved resistance to Rifampicin (RIF), the other major first-line TB drug used in 
conjunction with INH. It has been reported that approximately 95% of all rifampicin-resistant Mtb 
strains possess a mutation in the 81-bp region of RNA polymerase beta-subunit gene (rpoB) [73]. 
Pyrazinamide (PZA) is an antibiotic often incorporated into drug regimens to shorten treatment 
durations. Like other first-line drugs, Mtb has evolved resistance-conferring mutations in several 
genes. In 2016, it was reported that alterations in the pncA gene resulted in the inhibition of PZA 
activity whilst also correlating to resistance [74]. Further, additional studies showed that PZA 
resistance may be induced by mutations in the rpsA, panD and clpC1 genes [75-78]. Ethambutol (EMB) 
is another first-line anti-TB drug which is included in combination therapies to further prevent drug 
resistance. Mutations in the embB and ubiA genes have been shown to confer resistance to EMB [64, 
79, 80]. Resistance conferring mutations have also been reported in many second-line anti-TB drugs. 
The major compounds with clinical relevance have been summarised below (Table 2).  
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Table 2: Common Second-line ant-TB drug and the genes which confer resistance when altered. 
Adapted from Nasiri et al., 2017 [81] 
Second-Line Drug Drug Family Resistance 
conferring Genes 
Kanamycin, amikacin Aminoglycosides rrs 
Moxifloxacin, levofloxacin, 
sparfloxacin 
fluoroquinolones gyrA, gyrB 
Linezolid Oxazolidinone rplC, rrl 
Bedaquiline Diarylquinoline atpE 
 
1.6 The Cellular Envelope of Mycobacteria Tuberculosis: Peptidoglycan Synthesis, 
Remodelling and Cell Division 
1.6.1 Normal Mycobacterial Cell Division 
The host environment in which Mtb proliferates exerts both environmental and immunological 
stressors on the Mtb bacillus. Thus, Mtb has adopted several strategies to not only tolerate these 
stressors but to proliferate in this harsh environment and usher in TB. The strategies used to evade 
the host immune system are varied [82]. However, a key consideration should be given to the 
composition and remodelling of the mycobacterial cell wall during cell division to elucidate targets for 
therapeutic intervention.  
As mentioned, the majority of antibiotic compounds inhibit the formation or homeostasis of the 
bacterial cell wall. The mycobacteria genus displays significantly different cell wall morphology relative 
to traditional model bacterial systems such as Escherichia coli (E. coli) and Bacillus subtilis (B. subtilus). 
As such, the construction and maintenance of the cell wall in mycobacteria are, unsurprisingly, under 
the regulation of varying proteins relative to these model systems. This is further emphasised by the 
observation that at least a quarter of the annotated genes in the Mtb genome are attributed to the 
biogenesis and regulation of the cell wall [83].  
The proliferation and division of bacterial cells can be segregated into two stages, namely the 
elongation of the mother cell, and division of the elongated mother cell into two daughter cells during 
cytokinesis [84]. All bacteria which display rod-shaped morphology possess two poles present at the 
farthest ends of the bacillus: an old pole, which is a remnant of the mother cell, and a new pole, which 
is synthesised during division [84]. In model systems, the division of the elongated mother cell results 
in the formation of two symmetrical daughter cells. However, in mycobacteria, it has been widely 
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observed that the daughter cells which arise after division vary in size [85]. Two main hypotheses have 
been proposed to explain the asymmetrical growth of mycobacteria.  
The first hypothesis states that the growth of mycobacteria is unipolar due to the slow rate of growth 
observed at the new pole relative to the old pole [85]. However, it is now accepted that both poles 
contribute to elongation, though at highly variable rates which then facilitate the generation of 
daughter cells of many different sizes [85, 86]. The second hypothesis suggests a model where the 
growth rate at the poles, both old and new, is the same for most of the cell cycle  [86]. However, 
excessive growth is observed primarily at the old pole post-cytokinesis [86]. This asymmetrical growth 
facilitates daughter cells of varying sizes. 
Defining the underlying mechanism which elucidates the generation of asymmetrical progeny is 
generally confounded by whether researchers define cell division as the separation of daughter cells 
or rather as cytokinesis before physical separation [85, 86]. Regardless, both models agree on several 
observations; firstly, that growth at the poles varies, where rapid growth is observed at the old pole, 
and that the variation in growth rates results in the generation of the progeny of varying sizes [2, 86]. 
Secondly, daughter cells that contain the old pole are generally larger and elongate faster than the 
daughter cells which inherited the new pole. This implies that though both daughter cells are 
genetically identically there is an increased frequency of phenotypical variation during each division 
cycle. This phenotypically heterogeneous population of daughter cells has been shown to elicit vast 
cell wall remodelling during infection [84]. Given these lines of evidence, it has been hypothesised 
that this phenotypic variation may confer a selective advantage to the pathogen in the context of a 
constantly changing host environment. This hypothesis has been illustrated through the observation 
of the increased susceptibility to antibiotic treatments in larger bacterium possessing the old pole  
[85]. Importantly, there is also an asymmetric distribution of cell wall subunits and components, with 
one of the daughter cells receiving a newly formed cell wall [84]. 
The proliferation and polar division of bacteria are intrinsically dependent on the biogenesis of new 
cell wall material. This process is relatively simpler in model bacterial organisms in comparison to 
mycobacteria who, apart from peptidoglycan (PG), must concurrently synthesise mycolic acids (MA) 
as well as arabinogalactan (AG) [84]. The elongation of mycobacteria before septation is achieved 
through the action of a multi-protein complex called the elongation complex (described further 
below). After the mother-cell has elongated, the cell divides to form two daughter cells. The exact 
region at which this split occurs is highly variable and is thought to further contribute to the 
heterogeneity of the mycobacterial population [84].  
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The process of division is facilitated through a large complex of many proteins, collectively called the 
divisome [84]. It is hypothesised that some form of cross-talk exists between the elongation complex 
and the divisome which coordinates the synthesis of peptidoglycan away from the poles to the mid-
cell region, thus facilitating the formation of a septum where the cell will divide  [87]. The formation 
of the septum and its subsequent hydrolysis during physical separation is coordinated by a range of 
structural factors that stabilise the divisome and PG synthesis/hydrolytic enzymes which form and 
break down the cellular septum [88, 89]. These processes are essential for the generation of new 
daughter cells. 
Septation in both traditional model bacteria and mycobacteria is achieved through the polymerization 
of the self-activating GTPase FtsZ into a contractive ring-shaped structure commonly called the Z ring 
[90]. The site at which septation will occur, the provision of energy for the constriction of the cellular 
membrane during division, and the scaffold for subsequent PG remodelling enzymes are driven by this 
Z ring [90, 91]. Thus, the correct spatiotemporal orientation of the Z ring within a cell is essential for 
cell division and is highly controlled in mycobacteria. This is generally achieved through the 
modulation of genetic programs which impact the polymerization of the FtsZ and placement of the Z 
ring. For example in Mtb, Rv3660c overexpression has been shown to inhibit both FtsZ formation and 
the biogenesis of the septum [92]. In Mtb, the FtsZ ring is further regulated via phosphorylation. It has 
been shown in vitro that the serine/threonine protein kinase (STPK) Pkn ameliorates GTP hydrolysis 
via FtsZ, thus preventing its formation and subsequent ability to initiate septation [93]. Other intrinsic 
regulatory mechanisms have been reported, but these will not be discussed further in this 
dissertation. 
The physical separation of the daughter cells requires the hydrolytic breakdown of the newly 
synthesised septum [88]. In mycobacteria, one PG hydrolase (RipA) has been documented to be 
essential for the hydrolysis of the septum [94]. Its deletion has been shown to induce long strains of 
cells with multiple undigested septa [94]. Further, this PG hydrolase has been found to interact with 
an additional PG hydrolase, called RpfB [95]. In vitro experiments have shown that the interaction of 
these two enzymes results in the synergistic cleavage of PG [95]. However, this cleavage is confounded 
by the action of PonA1, a PG synthase which competes with RpfB to bind RipA [96]. It has been 
hypothesised that the ratio of RpfB to PonA1 is a potential mechanism which ensures that hydrolysis 
of the septum only occurs after PG synthesis. By contrast, in other model species, such as E. coli, the 
hydrolysis of the septum is achieved via the action of amidases and other PG hydrolases (FtsE and 
FtsX), however, few studies have assessed these hydrolytic enzymes in the context of Mtb [97, 98]. 
More recently, the functional role of RipA in the hydrolysis of mycobacterial division septa has been 
better characterised [99]. Their findings indicate that this endopeptidase is indispensable for regular 
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septation. The exact action of these canonical PG hydrolases in the context of mycobacterial cell 
division remains a gap in the literature.  
1.6.2 Remodelling of the Mycobacterial Cell Wall and Implications for Therapeutic 
Intervention  
The formation of the mycobacterial cell wall, and the remodelling of the complex macromolecules of 
which it is comprised, is an essential process which is under strict regulatory control to facilitate 
normal cell division and growth, virulence, as well as resistance to antibiotics [100-102].  Such 
remodelling is required for the insertion of new cell wall subunits for repair or growth, the 
incorporation of flagella, specialised secretion apparatus, or porins which are required for normal 
homoeostasis and cell functioning.  
The dynamic balance of cell wall biogenesis vs. degradation is an intricate process which is achieved 
via the coordinated action of multiple enzymes [103]. Dysregulation of this complex, dynamic process 
has deleterious implications for the bacterial cell and may result in the formation of non-viable 
progeny during binary fission. The targeted inactivation of one or several of the enzymes involved in 
the process of cell wall biogenesis and degradation have been successful strategies for the 
development of antibiotics such as penicillin [104, 105]. Common beta-lactam antibiotics have proven 
ineffective in the control of Mtb due to the thick mycobacterial cell wall and expression of beta-
lactamase, an enzyme capable of inactivating beta-lactam antibiotics [106]. 
The thick cellular envelope of Mtb is comprised of three distinct layers of macromolecules moving 
outwards from the cell membrane (Fig. 12); first is the peptidoglycan (PG) layer which is followed by 
the arabinogalactan (AG) layer and then finally the mycolic acid (MA) layer [84]. These three 
constituents of the cell wall are encompassed by a capsule made of noncovalently linked proteins and 
polysaccharides [84]. The abnormally high density of lipids found in the mycobacterium cell wall makes 
accurate Gram staining of this species difficult at best. They are, however, able to be staine d via acid-
fast dyes such as Ziehl-Neelsen [89]. The cell wall, or rather the enzymes which facilitate the cell wall 
synthesis, have been successfully used as targets for therapeutic intervention in the past; however, 
the increasing number of multiple-drug-resistant (MDR) and extremely drug-resistant (XDR) strains of 
Mtb [51] have highlighted the need for novel drugs or host-directed therapies which can disrupt cell 





Figure 12: Cell Wall of Mycobacterium tuberculosis showing the peptidoglycan (PG), arabinogalactan 
(AG), mycolic acid (MA) and capsule. Adapted from Kieser and Rubin, 2014 [84].  
 
1.6.3 Remodelling the Peptidoglycan (PG) Layer of the Bacterial Cell Wall 
During bacterial fission, the peptidoglycan of the mycobacterium is biosynthesised under the 
coordinated control of the elongation complex and numerous PF hydrolases (Fig. 13). These enzymes 
facilitate the synthesis of long polymers of disaccharide N-acetyl glucosamine and N-acetyl muramic 
acid (NA and NAM respectively) which are linked via the inclusion of peptide bridges [84, 102]. This 
murein (peptidoglycan) precursor is then bound to the membrane-anchored lipid carrier, thus 
facilitating the creation of the peptidoglycan lipid II [107]. The precursor of peptidoglycan (PG 
Precursor Lipid II) is synthesised in the cytoplasm of the bacillus and is transported across the cell 
membrane via the action of the transmembrane protein MviN (Fig. 13) [84, 102, 108]. The 
peptidoglycan is polymerised via the action of penicillin-binding proteins, glycosyltransferases, L, D- 
and D, D-peptidases [88]. More specifically, Penicillin-binding proteins PonA1/2 functionally integrate 
newly synthesised subunits into the existing structure of the peptidoglycan cell wall promoting 
elongation and the synthesis of the septum [84]. To ensure that the synthesis of the PG occurs in the 
right direction (directed to the poles of the cell), the elongation complex is anchored to the correct 
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place by Wag31, a homologue of DivIVA as seen in E. coli, and its interaction with CwsA, a cell wall 
synthesis protein [109, 110]. Overexpression of the CwsA has been shown in M. smegmatis to increase 
the localisation of the Wag31 at the poles, whilst its deletion results in a decreased localisation of 
Wag31 [111]. Most of the low molecular weight penicillin-binding proteins regulate the peptidoglycan 
synthesis via acting as D, D-carboxypeptidases. This regulation of polymerization is achieved via the 
removal of the terminal D-Ala residues at position-5 of the pentapeptides [112]. Yet-to-be-identified 
enzymatic hydrolases have been hypothesised to have an integral role in the opening of the 
peptidoglycan mesh for the insertion of these new precursors during processes of growth, repair and 
cellular division [84, 102]. The hydrolytic cleavage of the covalent bonds present in the cell wall is an 
essential process which allows for an increase in length with no change in thickness [88]. The newly 
integrated PG subunits are then crosslinked via the action of transpeptidases ( PBPA, PBPB, LdtA and 
LdtB) [84]. The cross-linking observed in Mtb is excessive relative to other well-studied model bacteria 
such as Escherichia coli (E. coli) with up to 80% of the peptidoglycan displaying atypical 3→3 peptide 
cross-links in contrast to the more traditional 4→3 peptide crosslink structure [84, 113]. The residues 
which make up the peptidoglycan layer have several modifications. Commonly, the glycolylation of N-
acetylmuramic acid (NAM), as well as the amidation of the d-Glu and mesodiaminopimelic acid 
(mDAP) residues of the peptide side chain, have been observed and published in the literature [114, 
115]. 
The silencing, or deletion, of specific enzymes involved in the remodelling of peptidoglycan, has been 
shown to have deleterious effects on the viability and pathogenicity of a bacterium. For example, in 
B. subtilis, the deletion of two endopeptidases, cwlO and lytE results in a complete loss of viability 
[116]. The inactivation of these enzymes can also affect the phenotype of the bacterium. As shown in 
a previous study within B. subtilis, the silencing of LytF resulted in the formation of slightly filamentous 
cells, whilst the double deletion of LytF with LytE exacerbated this phenotype greatly [117]. The 
separation of daughter cells requires the efficient cleavage of peptidoglycan. In E. coli, it has been 
shown that 13 periplasmic cell wall hydrolases can cleave almost any peptide, amide or glycoside bond 
[118]. This huge redundancy has led to the repeated observation that within E. coli, no single deletion 
of any cell wall hydrolase has impaired the growth and division of this bacillus [118]. The loss of 
function effect of amidase deficiency within model species has been well explored. This will be 




Figure 13: Diagram illustrating bacterial peptidoglycan and the site at which PG remodelling 
enzymes are active. A) Schematic representation of muropeptide. B) Cleavage points of PG 
hydrolases. Adapted from Irazoki et al., 2019 [119] 
 
It has been reported that in one cycle of bacterial fission approximately 45% of the cell wall material 
is turned over [120]. Thus, the loss of cell wall material, or the mechanism whereby peptidoglycan is 
completely newly synthesised, would impart significant energy costs to the bacillus and may impact 
survival [121, 122]. To mitigate this loss, bacteria employ several strategies to recycle cell wall 
material, particularly PG (Fig. 14). Whilst PG only accounts for a small percentage of the bacterial cell, 
during nutrient starvation or excessive competition for resources the recycling of PG may allow for a 
single round of division before entering the stationary phase [122]. The first studies to observe 
differences in cell wall recycling in gram-positive/negative bacilli reported a significant loss of PG 
material bacilli ranging from 25 - 50% in gram-positive strains [123, 124]. In contrast, E. coli was found 
to have a PG turnover rate ranging from  0% [123] to 5% [125]. This was later substantiated and 
elaborated on by Goodell and others, where those authors showed that E. coli had turnover rates 
similar to gram-positive bacteria, but were able to recover a large percentage of PG [120]. The 
mechanisms of murein recycling have been well elucidated in gram-positive bacteria, whilst a 
knowledge gap still exists for gram-negative bacteria. Several enzymes and proteins have been shown 
to have important roles in PG recycling, of which, and in the context of this dissertation, are cell wall 
amidases [122, 126]. In addition to the survival benefit, the recycling of PG may also play an important 
role in host immune evasion. Studies have shown that both the intact PG and PG fragments are 
immunomodulatory [127]. Thus, the knockout of enzymes which are important to the remodelling of 





Figure 14: Homeostatic recycling of bacterial PG. Adapted from Irazoki et al., 2019 [119] 
 
In the following sections, each of the classes of enzymes responsible for the remodeling of the cell 
wall (Fig. 13) mentioned above will be briefly discussed. 
1.6.4 Peptidoglycan Glycosidases 
Peptidoglycan, or cell wall glycosidases, are involved in the hydrolysis of the glycosidic bond or linkage 
found within the complex sugars of the bacterial cell wall. The hydrolysis of these linkages results in 
the formation of either a glucide hemiacetal or hemiketal [128, 129]. There are currently 135 families 
of glycosidase which can be separated into two categories viz; N-acetylglucosaminidases, and 
lysozymes. 
N-acetylglucosaminidases, comprising of two glucosaminidase activity domain families viz; glycosyl 
hydrolase family 3, or GHF-3 and the glycosyl hydrolase family 73, or GHF-73, have been found to be 
involved in the hydrolysis of the glycosidic bond in a range of complex sugars.  
Lysozymes and lytic transglycosylases (LTGs) act on the same glycosidic bond via two different actions 
which result in structurally different products. Lysozyme hydrolyzes the β1,4- glycosidic bond resulting 
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in a terminal reducing murein (MurNAc) residue which does not form a ring. Conversely, 
transglycosylases do not hydrolyse the same bond by cleaving it between the murein and N-
Acetylglucosamine (GlcNAc) - the resulting product being a 1,6-anhydro ring which forms at the 
murein residue [130]. Further, Lysozymes have been divided largely into 5 main subgroups namely 
Bacteria- (B), Chicken (C), Fungi- (F), Goose- (Goose) and Bacteriophage lambda (P) types [131]. In 
bacteria, and certainly mycobacteria, lysozymes remain poorly characterized with only three domains 
being currently recognized,  namely: glycosyl hydrolase family 22 (GHF-22), glycosyl hydrolase family 
24 (GHF-24) and glycosyl hydrolase family 25 (GHF-25) [132]. 
1.6.5 Peptidoglycan Peptidases 
Cell wall peptidases, or CWPs, are enzymes which cleave the amide bond between amino acids in the 
peptidoglycan of the cell wall [128]. Depending on their substrate specificity, cell wall peptidases can 
be categorized as either carboxy- or endopeptidases. Carboxypeptidases remove C-terminal amino 
acids whilst endopeptidases cleave the peptidoglycan peptide bond [132]. Three isoforms of 
endopeptidases have been observed: D, L-, L, D- and D, D-peptidase, which have a similar action, with 
different targets depending on the amide bond between L- and D- amino acids [133]. 
Currently, ten different domains have been published for cell wall peptidases namely: (i) cysteine 
histidine-dependent amidohydrolases/peptidases (CHAP), (ii) new lipoprotein C/protein of 60-kDa 
(NlpC/P60), (iii) peptidase M14 (PM14), (iv) peptidase M15 (PM15), (v) peptidase M23 (PM23), (vi) 
peptidase M74 (PM74), (vii) peptidase S11 (PS11), (viii) peptidase S13 (PS13), (ix) transpeptidase (TP), 
and (x) peptidase S66 (PS66) [132]. 
1.6.6 Peptidoglycan Amidases 
1.6.6.1 Identification and Function 
The peptidoglycan (PG) polymer is modified via the action of several remodelling enzymes such as 
transpeptidases, endopeptidases, carboxypeptidases, amidases and transglycosylases, which are all 
hypothesised to have key interactions in the synthesis, crosslinking and remodelling of the 
peptidoglycan during bacterial cell wall repair and growth [84, 88].  
Amidases are enzymes which have been hypothesised to be integral to peptidoglycan degradation 
during cell division, peptidoglycan recycling and the homeostatic regulation of osmotic pressure via 
the hydrolysis of the amide bond between the glycan strand and the stem peptide in peptidoglycan 
layer [88]. These enzymes have been found in multiple different species from viruses to eukaryotes. 
Within bacteria, most identified amidases are members of the bacterial autolytic enzyme system 
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important in the transport of a signal peptide across the cytoplasmic membrane.  In contrast to this, 
amidases identified in bacteriophage proteomes have been observed to act as autolysins which do 
not transport signal peptides, despite their ability to translocate across the cytoplasmic membrane 
[134, 135]. Amidases are classified based on their domain-containing proteins into either amidase_2 
(PF01510) or amidase_3 (PF01520), and studies which have assessed the catalytic domain have 
observed a high degree of structural conservation [136]. In  E. coli, five amidase homologues have 
been identified and have been allocated the names AmiA – AmiD and AmpD [137]. AmiA and AmiC 
vary in their transport to AmiB. Whilst the latter’s translocation is facilitated via Sec machinery, AmiA 
and AmiC are exported via the twin-arginine protein transport (Tat) system [138]. This export system 
has been documented to facilitate the movement of tertiary proteins containing one or more 
cofactors across the cytoplasmic membrane. Within a Bacillus polymyxa bacteriophage, the amino 
acid sequence of PlyA revealed that AmiA-AmiC are zinc ion containing metalloenzymes [139]. The 
ability of these enzymes to bind zinc may explain their translocation via the Tat pathway. 
The primary role of N-Acetylmuramyl-L-Ala amidases focuses on the biosynthesis, recycling and repair 
of the peptidoglycan sacculus. The PG sacculus largely resembles a net-like molecule comprising 
muramic acid residues linked via multiple peptide bonds [84]. Rearrangement of this sacculus during 
homeostasis and division is essential. This growth is simultaneously achieved through the insertion of 
newly synthesised PG subunits via PG synthases into gaps in the sacculus, created via the action of PG 
hydrolases which cleave the covalent bonds [140, 141]. This implies that the deletion of PG hydrolase 
genes would result in a bacillus which is unable to grow and divide. Despite multiple single - and multi- 
hydrolase knockouts, the phenotype of complete growth arrest has not yet been observed [129]. 
These data imply that there are multiple hydrolases, both known and unknown, which can 
compensate for the deletion of one or several knocked-out genes. Within E. coli alone, there exist 12 
known hydrolases which reside in the periplasm [142]. These periplasmic hydrolases, in which 
amidases are included, are highly active during the growth and binary fission of the bacillus. In one 
round of replication, it is estimated that a single E. coli bacillus loses approximately 45% of its total 
peptidoglycan via the direct activity of cell wall hydrolases [143]. Considering the primarily single-
layered structure of the PG, this percentage seems deleteriously high. The authors hypothesised that 
given the chemical compounds and turnover products involved, it is evident that the maintenance of 
the PG sacculus is achieved through the combined action of transglycosylases, endopeptidases and 
amidases. This is further elucidated in the separation of daughter cells via the cleavage of the cellular 
septum. Specifically, AmiA, an amidase homologue which is secreted into the periplasm of the E. coli 
cell, is an amidase_3 domain-containing protein whose deletion in E.coli results in atypical cell 
separation during division and the inclusion of multiple septa per cell [129, 137]. The bacterial 
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phenotype is that of a string of several connected daughter cells up to 15 µm long. Knockout of AmiC, 
another periplasmic amidase, resulted in a worsening of this phenotype which affected 20-30% of the 
E.coli population [137]. AmiB knockout did not display the elongated phenotype mentioned above, 
however, when knocked out in combination with AmiA, the additive effect worsened the atypical 
septation phenotype [137]. Further analysis of these filamentous mutants revealed that they 
displayed increased cell wall permeability and were more susceptible to antibiotic treatment [103, 
144]. 
1.6.7 The Role of Peptidoglycan and Amidases in the Host Immune Response 
Regarding the host immune response to bacterial PG, the recycling of cell wall material has both an 
energy benefit as well as plays a role in immune evasion. Previous studies have implied that PG 
recycling was largely observed in gram-negative bacteria;  excessive PG fragments were detected in 
gram-positive culture milieu [123]. Several amidases have been shown to have roles in the recycling 
of extracellular murein, and thus it is probable that the knockout of these enzymes may also affect the 
host immune response. [122]. 
Bacterial peptidoglycan, or the peptidoglycan fragments N‑acetylglucosamine (NAG) and 
N‑acetylmuramic acid (MurNAc or NAM), are a potent antigen for the induction of an effective host 
immune response for many species. In the Drosophila melanogaster model, muramyl tripeptide, a 
muropeptide released after the digestion of the peptidoglycan during a bacterial challenge, is 
recognised via peptidoglycan recognition proteins, or PGRPs, and subsequent classical Toll-like 
receptor (TLR) recognition which is essential for the induction of an efficient immune response [145]. 
Interestingly, many peptidoglycan recognition proteins are amidases, and in Drosophila melanogaster 
two main eukaryotic amidases, PGRP-SB1 and PGRP-LB, are intrinsically involved in the hydrolysis of 
the stem peptide of the peptidoglycan layer [146, 147]. The reduced ability of peptidoglycan 
recognition proteins to identify muropeptides in Drosophila melanogaster leads to a lessening of the 
TLR response and subsequent immune signalling. The role of TLRs in PG recognition is controversial. 
TLRs are transmembrane-spanning proteins which are found on the surface of both cells and 
intracellular endosomes. Initially, TLR2 was hypothesized to be the main pattern recognition receptor 
(PRR) responsible for the detection of PG [148-150]. In contrast to that work, a subsequent study 
postulated that the TLR2 activation observed in those studies was as a result of lipoteichoic acids and 
lipoproteins found within the cell wall as opposed to the PG itself [151]. In those studies, the authors 
show that these molecules often coprecipitate with bacterial PG and that with, sufficient purification, 
the host immune response facilitated via TLR2 activation can be ablated. Further, they showed that 
the pure PG activates NOD2 in TLR2 knockout macrophages. However, an alternative study proposed 
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that PG was, in fact, a TLR2 ligand [152]. In this study, the authors showed that purified soluble PG 
extracted from penicillin-treated bacteria, which was not incorporated into the cell wall and was thus 
lacking lipoteichoic acids and lipoproteins, was able to activate TLR2 and induce TNF. These differing 
results have been attributed to varying purification techniques, PG structure, bacterial species and PG 
cross-linking [153]. Together, these studies have highlighted the uncertainty of TLR2 as the PRR of PG. 
In mammals, four PG recognition proteins (PGLYRP1- PGLYRP4) have been identified [153]. They 
detect and elicit antibacterial activity through the detection of, and binding to, muramyl pentapeptide 
or tetrapeptide on the bacterial cell wall (Fig. 15) [154]. The cytosolic nucleotide-binding 
oligomerization domain-containing protein 1 (NOD1) and nucleotide-binding oligomerization domain-
containing protein 2 (NOD2) proteins are the two most well-characterized detectors of PG.  
 
Figure 15: Mammalian Innate Immune Signalling Pathways in Response to Bacterial Peptidoglycan. 
Adapted from [153] 
 
It has been reported that NOD1 identifies PG through the binding of the muropeptide γ-d-glutamyl-
meso-diaminopimelic acid (iE‑DAP) [155, 156]. Further, NOD2 identifies PG via muramyl dipeptide 
(MDP) which is formed via the acetylation of MurNAc otherwise known as NAM [157, 158]. For NOD1 
or NOD2 to detect these fragments, antigen needs to be present either outside the cell or within 
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phagosomes. Currently, solute carrier family 15 member 4,  or SLC15A4, is hypothesised to be the 
most likely transporter of PG antigen (iE-DAP and MDP) in both instances [159] (Fig. 15). The binding 
of these ligands to either NOD1 or NOD2 respectively results in the oligomerisation to RIPK2, which 
subsequently results in the activation of two pathways, namely the inhibitor of nuclear factor-κB (IKK) 
complex leading to activation of nuclear factor-κB (NF‑κB), or activation of mitogen-activated protein 
kinase kinase kinase 7 (TAK1) and the mitogen-activated protein kinase (MAPK) signalling cascade 
[160]. Both of these pathways initiate the production of inflammatory cytokines and chemokines 
which are essential for the host immune response and antigen presentation [160].  
Bacteria have evolved several strategies to mitigate immune detection, elicit chronic infection and 
increase virulence. The most effective methods of immune evasion occur through various 
modifications to the PG. Studies in Streptococcus pneumoniae, Listeria monocytogenes and 
Staphylococcus aureus have demonstrated that these pathogens can evade the host immune system 
and enhance their pathogenicity through the deacetylation or the acetylation of the PG sugar 
backbone via the genes, pdgA and O‑acetyltransferase, respectively. [161-163]. More specifically, the 
deacetylation of NAG or MurNAc has been shown to abrogate NOD1/2 and inflammasome activation 
[164]. Additionally, Mtb has displayed the ability to evade the NOD1 host immune response via the 
amidation of the meso–diaminopimelic acid (mDAP), thus removing the substrate required for the 
formation of iE-DAP, the ligand of NOD1 [127, 165]. However, NAM residues within the PG polymer, 
which have been glycolylated, are well recognised via NOD2 and facilitates the induction of 
inflammatory cytokines in macrophages infected with Mtb [166, 167]. Mycobacterium tuberculosis 
muropeptides have been shown to potently induce the host innate immune response and can 
modulate immunity to infection [166]. Further, Mycobacterium tuberculosis muropeptides have been 
shown to play an important role in normal granuloma formation [168-170]. 
The dysregulation of the genes - and thus enzymes - which may play key roles in the remodelling of 
the mycobacterium cell wall, as well as the contribution of degraded peptidoglycan, may result in 
modulation of the host immune response to Mtb. 
1.6.7.1 Mycobacterial-Specific Amidases 
The mycobacterial cell wall is a unique structure which is distinct from that of well characterised 
bacterial models such as E. coli. As such, the inherent role of PG remodelling enzymes is expected to 
vary relative to the PG hydrolases observed in other model systems. The exact role of  amidases in the 
context of mycobacterial homoeostasis and replication remains unclear. However, two recent studies 
have identified the crystal structure of Rv3717 (herein referred to as Ami1), a mycobacterial amidase 
which shares structural similarity to amidase_3 domain-containing amidases and has the functional 
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ability to cleave peptidoglycan [171, 172]. The hydrolytic activity of this enzyme was functional with 
the cell wall constituents of other bacteria, highlighting the degree of structural conservation 
observed [172]. In-depth biochemical analysis Rv3915 (herein referred to as Ami2), a peptidoglycan 
hydrolase isolated from Mtb, revealed distinct amidase activity [97]. In addition to Ami1 and Ami2, 
two more amidases have been identified in Mtb and Mycobacterium smegmatis alike. These enzymes 
have been designated the names Ami3 (Rv3811, MSMEG_6406) and Ami4 (Rv3594, MSMEG_5315) 
[98]. Both Ami3 and Ami4 are classified under the amidase_2 domain-containing family of cell wall 
hydrolyzing enzymes [98]. Ami1-Ami4 are potentially integral peptidoglycan remodelling enzymes in 
Mtb, however, this is yet to be fully elucidated. 
As mentioned above, previous studies which have looked at the function of these enzymes in model 
organisms such as E. coli have found that the knockout of amidase homologues resulted in a bacterial 
phenotype which displayed atypical septation during binary fission and drastically increased the 
incidence of filamentous-like bacteria aggregates composed of multiple individual bacteria [103, 128, 
173]. More recently, a similar phenotype was observed in non-pathogenic Mycobacterium smegmatis 
where Ami1 was knocked out via using two-step allelic exchange mutagenesis [174]. The amidase 
knockout again was shown to display a phenotype of dysfunctional septation and atypical filamentous 
growth, which was reversed via complementation (Fig. 16) [174]. Interestingly, the authors observed 
a two- to fourfold increased susceptibility to a range of cell wall targeting antimicrobial agents, as well 
as increased cell permeability in Ami1 defective bacteria [174]. 
These lines of evidence suggest that amidases play an important role in normal mycobacterial cell wall 
remodelling, most notably during binary fission, as well as potentially preserving tolerance to cell wall 
targeting antibacterial compounds. Inhibition of peptidoglycan remodelling enzymes may potentially 
I.) convey a pharmacokinetic advantage to existing TB treatments due to dysfunctional cell division or 
II.) improve host immune responses that ameliorate disease outcome. The immune response, 
phagocytic ability, and virulence of these Mtb mutants in both the human and murine model of Mtb 





Figure 16: Knockout of Ami1 in Mycobacterium smegmatis A) Scanning electron microscopy 
displaying filamentous phenotype and atypical septation relative to WT (mc2155) B) Ami1 knockout 
resulted in a mutant strain with an increased proportion of septa-contain cells which are composed 
of multiple cells resulting in C) a significant increase in length. Adapted from Senzani et al. 2017 [174]. 
 
1.7 The Role Epigenetics in Tuberculosis – Importance and Implications. 
Mtb can tolerate, as well as proliferate, within the intracellular environment of innate immune cells. 
Infected individuals can be segregated into two categories: active disease patients, and individuals 
who are latently infected with Mtb (LTBI). The factors which contribute to the chronic persistence of 
Mtb to the host immune response and its later activation remain poorly understood. Some reports 
have shown that several bacterial factors are involved with the alteration of the Mtb virulence and 
induction of dormancy, without hampering their ability to enter cells. For example, resuscitation 
promoting factors (RPFs) have been shown to play integral roles in this phenomenon [175]. The 
epigenetic modulation of host nucleic acid can alter various cellular mechanisms ranging from gene 
expression, DNA repair and recombination, and may play a significant role in the resuscitation and 
subsequent immune response to Mtb. Whilst not always heritable, epigenetic alterations may be 
passed along during cell division, homeostatic growth and repair processes. These changes are not 
terminal and may be altered or deleted during the ontogeny of the cell. Methylation, acetylation, 
phosphorylation and ubiquitylation are all methods by which these alterations are achieved [176, 
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177]. Several microorganisms, including pathogenic species, have exhibited the ability to alter the host 
epigenome to disrupt key cellular processes involved with immunity, apoptosis and other defensive 
cellular mechanisms [178]. Mtb has been reported to exploit these methods, specifically histone 
modification, the expression of non-coding RNAs (ncRNAs), and DNA methylation to facilitate its 
persistence in the human lung and evade immune control.  
1.7.1 Mycobacterium tuberculosis and Histone Modification 
Histone modification refers to the alteration of the amino acid residues situated on histone tails, the 
primary protein components of the eukaryotic chromatin system within the nucleus. These alterations 
change the organisation and functional ability of the chromatin, thus affecting the ability of the 
chromosome to interact with nuclear RNA and proteins. This change in the ability of the chromatin to 
function has implications for gene expression, cellular growth and division, as well as the 
establishment of a successful host immune response. Chromatin alteration is facilitated through the 
actions of multiple enzymes, namely: histone deacetylases (HDACs), histone acetyltransferases 
(HATs), histone demethylases (HDMs), histone methyltransferases (HMTs), kinases, and phosphatases 
[179]. These chromatin modifications can also determine how densely the genetic material is 
organized into the complex structures by either active chromatin or inactive chromatin. Active 
chromatin is linked to post-translational modification of histone-3-lysine-4 residue trimethylation, 
whilst inactive chromatin is linked to histone-3-lysine-9 residue trimethylation [180].  
During Mtb infection, the host immune system upregulates the production of IFN-γ which binds to, 
and activates, innate antigen-presenting cells (APCs) such as macrophages, thus increasing their 
antimicrobial activity. This is accomplished primarily through the upregulation of MHCII genes. Mtb 
can subvert this process. The binding of IFN-γ to surface receptors of APCs activates the Janus tyrosine 
kinase-signal transducer and activator of transcription1 (JAK-STAT1) pathway which, among other 
functions, can upregulate the class II transactivator (CIITA) which subsequently upregulates MHCII 
genes and is essential for the presentation of antigen [181]. In 2012, a study interrogated the different 
methylation patterns associated with BCG vaccination in immune-compromised (SCID) mice [182]. 
Those authors found that mice which received the BCG vaccination led to increased survival relative 
to unvaccinated control mice. Further, they showed that this survival benefit was facilitated by the 
epigenetic modifications of histone H3 trimethyl lysine4 (H3K4me3), which resulted in the 
reprogramming of the NOD2 gene within monocytes. A previous study reported that Mtb can prevent 
the gene expression of the CIITA transactivator via the secretion of a 19-kDa protein called Rv3763, 
which directly prevents the acetylation of histones 3 and 4 [181]. Further, it has been shown that Mtb 
can induce both methylation and acetylation marks in host DNA [183]. In this study, the authors 
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reported that Mtb infection significantly reduced H3K4 methylation as well as CIITA acetylation in 
primary macrophages following infection. In the absence of this protein, the host immune response 
was significantly more robust. Recently, Mtb was shown to modulation host autophagy through the 
increasing the acetylation at histone H3 [184]. Further, Rv3423.1, first isolated from Mtb infected 
primary macrophages, was shown to confer intracellular survival when incorporated into M. 
smegmatis via its histone acetyltransferase activity at H3K9 and H3K14  [185]. More recently, Koo et 
al. showed that a chronic immune response against Mtb (CDC1551), a susceptible lab strain, was 
sufficient to clear the pathogen. However, under the same conditions utilising the hypervirulent strain 
HN878, the immune response was unable to clear the infection [186]. Whilst the exact mechanism 
was not reported in that paper, their results reinforce the hypothesis that Mtb can alter the host 
immune response to encourage immune evasion and intracellular survival. Further illustrating the 
mechanisms of intracellular Mtb-macrophage epigenetic dynamics, a 2016 study highlighted the role 
of Alu element transposition during the early host innate immune response [187]. Specifically, they 
showed that, during infection, histone modifications to H3K4me1 resulted in the detection of a 
significant number of transcription factor binding sites, which are important in macrophage 
differentiation and immune responses during infection [187]. Further, they provided evidence to show 
that, through this epigenetic reprogramming, Mtb-infected macrophages can alter their cholesterol 
metabolism and apoptotic characteristics to kill Mtb. 
1.7.2 Mycobacterium tuberculosis and DNA methylation 
DNA methylation is utilised in a myriad of organisms in the regulation of gene expression, cellular 
development and differentiation, as well as genetic reprogramming [50]. The silencing of genes can 
be achieved by the methylation of CpG sites, thus preventing the interaction of transcription factors 
to their specific CpG island [188]. DNA methylations, such as these, are hypothesised to be less 
reversible and are more stable than histone modification [188].  
In human cell line studies, significant epigenetic changes have been observed in Mtb infected THP -1, 
a human monocyte-like cell line, relative to uninfected controls, with the caveat that the degree of 
epigenetic change is variable depending on the strain and virulence of the Mtb isolates used during 
infection [189]. It has also been reported that Mtb-induced methylation may play a role in stress 
response [190]. Here, the authors provide evidence showing that a DNA methyltransferase in Mtb, 
called MamA, plays an important role, albeit Mtb strain-specific response, to hypoxic stress. More 
recently it was shown that Mtb can produce Rv2966c, a 5-methylcytosine-specific DNA 
methyltransferase, which is secreted by Mtb and is translocated to the host nucleus [191]. There, 
Rv2966c methylates host DNA in a non-canonical non-CpG specific manner to repress the host 
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immune response and promote bacterial survival. Further, it has been shown that Rv1988, a secreted 
Mtb methyltransferase, can translocate to the host nucleus and methylate histone H3 at H3R42 [192]. 
This methylation was then shown to be correlated with the inhibition of anti-TB genes and increased 
the ability of Mtb to survive in macrophages and mice. 
In a recent clinical study, researchers interrogated DNA methylation patterns in patients suffering 
from TB [193]. In this study, they showed that TB patients possessed DNA hypermethylation patterns 
in the IL-2/STAT5, TNF/NF-κB, and IFN-γ intracellular signalling pathways. Further, they identified 
specific methylated genes within these pathways, which were correlated with decreased immune cell 
functionality and a worsened host immune response to Mtb [193]. This study illustrates the ability of 
Mtb to subvert the host immune response via the action of DNA methylation. 
DNA methylation markers may probably be used as a reliable diagnosis of active and latent TB in the 
future. A recent study has already highlighted the feasibility of this [194]. In that paper, the 
researchers show that, via the assessment of the DNA methylome, it may be possible to identify not 
only TB positive individuals but also to distinguish between latent and active infection [194]. 
1.7.3 Mycobacterium tuberculosis and the regulation of non-coding RNAs 
Current research has exhibited the critical roles of non-coding RNAs (ncRNAs) during various 
homeostatic mechanisms such as oncogenesis, apoptosis and cellular ontogeny [195]. Small ncRNAs, 
such as microRNAs (miRNAs), are important regulatory molecules which alter gene expression at a 
post-translational level [82, 196]. This occurs via the binding of the miRNA to the 3’UTR of mRNAs, 
thereby modifying their expression. Despite a growing interest in these molecules in TB, their roles in 
Mtb-host infection remains largely unknown [82].  
Current research is increasingly informing on the intrinsic ability of Mtb-induced miRNAs to ameliorate 
the host immune response, thus contributing to pathogenesis. To illustrate this point, it has been 
shown that Mtb-infected dendritic cells and macrophages display a significant difference in the 
expression of numerous miRNAs relative to uninfected controls [197, 198]. Further, variations in strain 
and virulence have also been shown to induce differing miRNA expression profiles [199, 200]. Within 
the human-Mtb model of infection, it has been reported that BCG can suppress the activity of several 
IFN-y producing immune cells such as natural killer (NK), and CD8+ and CD4+ T cells via the 
downregulation of miR-29 [201].  
In mice, it has been shown that the targeted knockout of miRNA, miR-155, resulted in a heightened 
susceptibility to Mtb infection, highlighting the critical role this miRNA plays in the immune response 
to Mtb [202]. Further, in the human model of Mtb infection, Mtb-induced miR-155 was shown to 
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promote intracellular survival through the subversion of autophagy via its action on ATG3 [203, 204]. 
Additionally, Mtb has been shown to ameliorate the host immune response through the induction of 
miR-125b [205]. In that study, the authors show that miR-125b can inhibit the secretion of TNF during 
Mtb infection in mice. More recently, the roles of microRNA-143 and microRNA-365 in Mtb infection 
were elucidated [206]. In the study, the authors show that these miRNAs can promote bacterial 
growth in alternatively activated macrophages via their interaction with several transcription and host 
factors. Among others, several notable miRNAs have been identified which are induced by Mtb and 
result in a reduction of the host immune response: miR-99b [207], miR-125a [208], miR-33 [209], miR-
132[210], miR-26a[210, 211], miR-20b [212] and miR-144 [213]. 
Like miRNAs, long non-coding RNAs (lncRNA) are believed to play important roles in TB pathogenesis. 
RNA sequencing data has shown an increased abundance of these molecules in the lungs of infected 
mice [214], however, few studies have managed to identify specific Mtb-induced lncRNAs which may 
modulate the host immune response [82]. Recently, the lncRNA, PCED1B-AS1, which is downregulated 
in Mtb infected patients, was shown to act as a molecular sponge to miR-155, thus enhancing 
autophagy and decreasing macrophage apoptosis in vitro [215]. Other lncRNAs which have been 
shown to be associated with TB are detailed in Table 3 below. 
Table 3: Additional Long non-coding RNAs which are upregulated/downregulated during Mtb 
infection. Adapted from Fathizadeh et al., 2020 [216] 




↑ Associated with Impaired T cell activation and host 
immune response 
[217] 
ENST00000422183 ↓ Associated with Impaired T cell activation and host 
immune response 
[217] 
Lnc-AC145676.2.1-6 ↓ Impaired TLR signalling [218] 
Lnc-TGS1-1 ↓ Associated with thrombocytopenia during TB 
treatment and impairment of TLR signalling 
[218] 
XLOC_014219 ↑ Associated with impaired CD8+ T cells activity [219] 
ENST00000427151 ↑ Associated with B cell activation during TB  [220] 
ENST00000354432 ↑ Associated with renal dysfunction during TB [220] 
NEAT1 ↑ Associated with prolonged Mtb infection via the 
reduction in IL-6 
[221] 
BC050410 ↑ Associated with downregulation of IFN-γ and TNF-α [222] 
MIR3945HG V1 and 
MIR3945HG V2 
↑ May be beneficial as a TB biomarker  [223] 






Taken together these lines of evidence emphasise the significant impact that ncRNAs may have on the 
course of TB pathogenesis. Further, this evidence shows the intrinsic ability of Mtb to epigenetically 
reprogram the host immune response to elicit a survival benefit of the bacillus. Finally, these data 
illustrate that modern sequencing technologies have emerged as a robust, unbiased and powerful 
toolset by which we can interrogate host-pathogen interactions. Utilising these, and future, 
technologies will allow researchers to discover and characterise numerous ncRNAs which remain to 
be discovered and may be of far-reaching therapeutic and clinical significance. 
1.8 What is RNA-seq? 
Traditionally, gene expression changes were first measured via polymerase -chain-reaction, or PCR 
utilising primers, dNTPs and Taq polymerase in a method which was, famously, first pioneered by Kary 
Mullis in 1983 [225, 226]. Theoretically, this technology allowed for the single-copy detection and 
amplification of gene transcripts. Soon after the discovery, this technology was improved upon 
through first the addition of fluorescent dyes, such as SYBR green, and later by probes, such as 
commercially available TaqMan® which bind to the cDNA products. This innovation allowed for not 
only the detection of specific gene transcripts but quantification of them as well [225, 227].  
RNA sequencing (RNA-seq) greatly improves further on the traditional PCR and qPCR methodology by 
the high throughput parallel sequencing of RNA. Its advent, more than 10 years ago, has been quoted 
to have facilitated the “second transcriptomic revolution” [228]. RNA-seq was developed from existing 
next-generation sequencing platforms which were actively used for high throughput analysis of DNA. 
In RNA-seq, RNA samples are reverse transcribed into a cDNA library which is then sequenced. The 
subsequent reads (sequence data) are then bioinformatically analysed in silico. “Depth” is the 
technical term used in sequencing studies, which alludes to the number of reads that was acquired. 
This data is generally used to assess differential gene expression (DGE) or identification of novel 
transcripts. The first genome-wide studies which utilized RNA sequencing were run in 2008. These 
studies were carried out in both mice and humans and yielded a range of 5- to 150-million reads with 
short read length in the range of 25 -32bp [229, 230]. Other species were subsequently sequenced. 
The first bacterial RNA-seq data provided approximately 5 million reads with an average length of ±37 
bp [231-234]. Current short-read RNA sequencing technologies can sequence almost 100 - 1000 times 
more reads per run, whilst the long-read application can sequence fragments which are in the range 
1 -50 kb [235].  
RNA-seq technology, and its continued improvement, have shaped our understanding of biology and 
disease by revealing the presence and action of non-coding RNAs [236, 237], enhancer RNAs [238], as 
well as highlighting the extent of RNA splicing [239] in a myriad of biological models and species. In 
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the future, the utilisation of this technology will allow us to leverage the insights it brings to improve 
health, fight disease and better understand the natural world. 
1.9 A Dual RNA-seq Approach to Studying Disease 
RNA sequencing is a powerful tool which has allowed researchers to better elucidate unknown cellular 
mechanisms in a range of organisms in a high throughput, robust fashion. Among the most intricate 
interactions which RNA-seq can inform on is that of between a host and pathogen during infection. 
During infection, a vast number of cellular processes are activated both within the host immune 
system and within the invading pathogen. These complex interactions are made more multifarious by 
the action of unknown genes, RNAs and molecules which may be contributing to immune evasion or 
sensitivity. Recent studies have illustrated that the unbiased interrogation of changing global 
transcriptional profiles within the host and pathogen thus remains a key method to elucidating these 
immune events, and may provide key knowledge to develop and refine treatment strategies [240]. A 
dual RNA-seq approach is beneficial as it allows for the parallel understanding of both transcriptomic 
changes within the pathogen as well as within the host, with both accuracy and depth. 
Initially, viral, parasitic and fungal infection models, whose transcripts were structurally similar to the 
host, were the first to be interrogated using dual RNA-seq [241-244]. However, the intrinsic biological 
difference between bacteria and eukaryotic cells (Table 4) are namely total RNA availability and 
composition eukaryotic cells typically have as much as two orders of magnitude more RNA than 
bacterial cells)., These obstacles required additional refinement of the experimental protocols and 
advancement of available technologies [240]. Vogel et al. [228] were one of the first research groups 
to postulate the feasibility of this technology to a bacterial infection model, and were the first to coin 
the term “dual RNA-seq”. In a later study, the same group demonstrated that with sufficient 
improvement of available technologies not only could dual RNA-seq work but that it could also provide 
valuable insights into novel regulatory ncRNAs elicited during host-pathogen interactions [245]. 
Despite early bacterial-host dual RNA-seq studies being exploratory, many have provided new 
understandings to the host immune response during infection.  
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Table 4: Different Types of RNA in Bacteria and Eukaryotes. Adapted from Westerman et al., 2012 
[228] 






rRNA ± 80 n/a • Cleaved from precursor transcripts  
• 120nt (5S), 1,500nt (16S), 2,900nt (23S) 
tRNA 14-15 n/a • Cleaved from precursor transcripts  
• 75–95nt 
mRNA 4-5 n/a • Polycistronic  
• Uncapped  
• Variable polyadenylation state (<50 As) 
tmRNA <1 n/a • Processing similar to that of tRNA  
• 230–400nt 
sRNA Varies n/a • Processed or unprocessed  
• ~50–300nt 
Eukaryotic Cell 
rRNA ± 80 Cytoplasm • Processed or unprocessed  
• 120nt (5S), 160nt (5.8S), 1,874nt (18S), 
4,718nt (28S) 







Nucleus • U-rich 
• ~150nt 
snoRNA Nucleolus • U-rich 
• ~60–300nt 
• Two major classes (H/ACA and C/D box) 
scaRNA Cajal bodies • Similar to snRNAs 
mRNA Cytoplasm/nucleus • Processed from pre-mRNA via splicing 
• 5ʹ capped 
• 3ʹ polyadenylated (~250 As) 
miRNA Cytoplasm/nucleus • Processed 
• 21–23nt 
siRNA Cytoplasm/nucleus • Processed 
• 20–25nt 
piRNA Cytoplasm/nucleus • Processed 
• 24–31nt 
lncRNA/lincRNA Cytoplasm/nucleus • Heterogenic 
 
Early Chlamydia trachomatis dual RNA-seq studies reported evidence showing that iron acquisition, 
coupled with host immune dampening, was one of the strategies which allowed these bacteria to 
infect human epithelial cells and induce fibrotic scarring [246]. Later, another study utilizing this 
technology found that whilst uropathogenic Escherichia coli (UPEC) – host responses were similar 
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when assessed for differing bacterial strains, transcriptomic differences were observed when 
compared to the pathogenicity of the strains used [247]. Further, the parallel analysis of host-
pathogen transcriptomes in the Haemophilus influenza mucosal epithelial cell model highlighted the 
critical role of oxidative host responses, as well as the subsequent strategies by which this was evaded 
by the pathogen [248]. Very recently, dual RNA-seq was used to differentiate distinct macrophage-
lineages within the murine Mtb infection model via their transcriptomic gene signature [249]. From 
their sequence data, they were able to show that permissive Mtb infected alveolar macrophages 
sustained bacterial replication through increased association with iron and fatty acid storage 
pathways. In contrast, they showed that interstitial, or recruited macrophages, were able to restrict 
Mtb growth and were associated with iron sequestration and higher expression of NO [249]. 
Together, these studies highlight the power of dual RNA-seq to elucidate the intrinsic cross-talk of 
pathogen and host which contribute to intra-macrophage survival or sensitivity and supports the 
hypothesis of unknown mechanisms in other disease models and during homeostasis. I n the following 
study, we aim to explore and reconstruct the dynamics of epigenetic and transcriptional modifications 
and their effector proteins in human macrophages following Mtb infection, as well as identify 
associated noncoding RNAs which are correlated with these epigenetic changes.   
1.10 Problem Statement 
In recent years, TB has become the leading infectious killer worldwide with the highest-burden being 
experienced in developing countries within Sub-Saharan Africa and South-East Asia. The effectiveness 
of the host immune system, as well as the ability of first-line drugs to control Mtb, the causative agent 
of TB, is primarily hampered by, amongst other factors, the characteristically thick cell wall observed 
in Mtb. This wall is composed of mycolic acid, peptidoglycan and arabinogalactan which are all 
encompassed in a capsule. These multiple contributing layers are essential for normal physiological 
functioning, osmoregulation, structure, antibiotic resistance and homeostasis. The targeted 
dysregulation of the complex processes essential for the remodelling and repair of the cell wall during 
cell division may improve disease pathology or increase the efficacy of modern TB therapies. Further, 
a greater understanding of host-pathogen dynamics would allow for the discovery of novel gene 
targets which can be exploited for novel ant-TB treatment. 
1.11 Aims 
• We aim to explore mycobacterial survival and modulation of the host immune responses to 
infection of macrophages using amidase defective strains of Mtb. Further, we aim to assess the 
virulence of these amidase defective mutants and to test their sensitivity to existing drug therapies 
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both in vitro and ex vivo as to ascertain the potential of amidase homologues as future targets for 
novel drug development. 
• Further, we aim to develop a reliable method for segregating both host and pathogen RNA in the 
Mtb – human macrophage model of infection. Utilising this methodology, we aim to longitudinally 
assess the transcriptional variation in both host and pathogen and correlate this to observable 
epigenetic changes in the host. 
1.12 Hypothesis 
Within the context of Mtb replication and the remodelling of the cell wall, we hypothesise that the 
disruption of cell wall remodelling processes, via the knockout of amidase homologues, has the 
potential to elucidate novel vulnerabilities in the restructuring of the peptidoglycan sacculus which is 
the prerequisite for successful cell division. These vulnerabilities have the potential to be exploited for 
novel drug design or the repurposing of existing therapies to improve TB outcome. Specifically, we 
hypothesise that amidase deficient mutants may display atypical septation, increased length and 
dysregulated binary fission which will modulate the host immune response.  Lastly, we hypothesise 
that the segregation of the host and pathogen RNA is possible, even at relatively low MOI.  
1.13 Objectives 
To achieve the aims set out above, the general objectives of this study are as follows; 
• To assess the immune response and mycobacterial survival in primary and cultured murine bone 
marrow-derived macrophages (BMDMs) which have been infected with amidase defective 
mutants (Δami1, Am1-Complement, Ami4, Ami4-Complement and H37RV) of Mtb. 
• To assess the immune response and mycobacterial survival of the same Mtb mutants in human 
monocyte-derived macrophages (MDMs) and the human monocytic cell line, THP-1 cells. 
• To assess the virulence of Mtb mutant’s defective in amidase in the murine model of TB infection 
as well as to assess the host immune response to infection in vivo. 
• The effect of first-line drugs as well as PG-specific antibiotics will be assessed in vitro, ex vivo and 
in vivo.  
• The high-throughput generation of primary human monocyte-derived macrophages will be 
optimised for downstream Mtb infection experiments. 
• Lastly, a protocol for the efficient segregation of human and mycobacterial RNA from Mtb-
infected human macrophages will be optimised. 
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2 Chapter Two 
General Materials and Methods 
 
2.1.1 Ethics 
All the experiments performed were done in accordance with the Animal Research Ethics Committee of 
South African National Standard (SANS 10386:2008) and University of Cape Town, South Africa for practice 
on animal procedures. The protocol (Permit number: 015/40 and 015/36) has been approved by the 
Animal Ethics Committee, Faculty of Health Sciences, University of Cape Town (Cape Town, South Africa). 
Further, this study has been ethically approved for the experimentation with human tissues (MDMs) 
within the context of the research question detailed above (Human ethics protocol: HREC 732/2015).  
2.1.2 Cells and Reagents 
To analyse the virulence and host protective responses of the Ami-deficient Mtb mutants within the 
murine model of infection, and the optimisation of the dual-RNA seq methodology, three model systems 
were investigated; 
2.1.2.1 Human Monocyte-Derived Macrophages (MDMs) 
For human monocyte-derived macrophages (MDMs), healthy-donor leukopaks were acquired from 
donors from the South African National Blood Service in Cape Town, South Africa. Leukopaks were 
standardised for age, sex and race. Standard pathological testing is conducted by the Western Cape Blood 
Transfusion Service (WCBTS) on all blood to ensure its free from HIV, Hepatitis B and C, and Syphilis. 
PBMCs were isolated via density centrifugation. Classical (CD14++CD16–), non-classical (CD14+CD16++) and 
intermediate (CD14++CD16+) monocytes were purified via negative selection utilising the MojoSort™ 
Human Pan Monocyte Isolation Kit (Biolegend) and were differentiated into monocyte-derived-
macrophages (MDMs) in standard RPMI media supplemented with 10% fetal calf serum and 50 ng/uL 
recombinant human M-CSF over 7-days. 
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2.1.2.2 Murine Bone Marrow-Derived Macrophages (BMDMs) 
To generate BMDMs, pluripotent stem cells were extracted from the femur and tibia bones of the C57BL/6 
mouse strain. These cells were differentiated for 10-days at 37°C to bone marrow-derived macrophages 
in standard Plutznik media comprising of Inactivated Fetal Calf Serum (10% v/v), Inactivated Horse Serum 
(5% v/v), L929 conditioned medium (30%), 2mM L-glutamine, 1 mM sodium pyruvate, 50 U/ml penicillin, 
50 ug/ml streptomycin, 50uM -Mercaptoethanol and DMEM (50%) as described previously [250]. Post-
differentiation, BMDMs were then harvested and plated into 96-well plates (Nunc, Denmark) and cultured 
overnight to ensure adequate adherence. To polarise these cells, they we re cultured in DMEM media 
(Gibco) supplemented with 10% FCS and IFN-γ (100 U/ml, BD Biosciences, San Jose, CA). Activated BMDMs 
were then infected with Mtb at an MOI of 1. 
2.1.2.3 THP-1 Cell Line 
THP-1 were utilised for the optimisation of RNA extraction as well as other experimental troubleshooting. 
The THP-1 (ATCC® TIB-202™) cell line was purchased from the ATCC. The cells were cultured at 37°C and 
CO2 (5%). A cellular concentration of 0.5 x106 cells/ml was maintained at all times in RPMI-1640 media 
(Gibco) supplemented with β-mercaptoethanol (0.05 mM) and fetal bovine serum (10% v/v). The cells 
were passaged every 2-3 days. For cryopreservation, approximately 10-20 x106 were resuspended in 
culture media supplemented with DMSO (5% v/v) and stored at -80°C. 
2.1.3 Bioinformatics and Experimental Mycobacterium tuberculosis Strains 
M.tb mutants utilised in this study were generated by our collaborators at the University of Witwatersrand 
(Dr Sibusiso Senzani and Professor Bavesh Kana). For a full breakdown of methods and results, please 
reference the original PhD dissertation [251].  
In short, Mtb strains deficient in four amidase-encoding genes; Rv3717 (Ami1), Rv3915 (Ami2), Rv3811 
(Ami3) and Rv3594 (Ami4) were constructed using two-step allelic replacement with a suicide plasmid and 
a selectable lacZ and counter-selectable sacB markers [174].  This involved the cloning of homologous 
upstream and downstream regions to create in-frame, unmarked gene deletions that were transferred to 
the mycobacterial chromosome. Vectors for genetic complementation were generated by cloning wild-
type genes, with upstream promoter elements or associated genes into a vector that will integrate into 
the mycobacterial chromosome. Mycobacterial colonies were streaked on 7H11 media and left at 37°C 
for 14 days. Single colonies were then picked and incubated in liquid 7H9 broth at 37°C until an optical 
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density (OD600) of at least 0.6 was reached. Stocks were stored down in 2 mL cryovials at -80°C and 
thawed as needed.  
2.1.3.1 PCR Validation of Amidases Deficient Mycobacterium tuberculosis strains 
To ensure that the strain-specific knockout was present, Mtb amidase deficient strains were assessed via 
PCR. In brief, Mycobacterium stocks were then streaked on 7H11 agar plates and incubated at 37˚C for 2-
4 weeks. A single colony was then picked and inoculated in 50 µL sdH2O and heat-inactivated at 95°C for 
10 min. 25 µL chloroform was added, and the solution was centrifuged at maximum speed for 10 minutes. 
The top layer was removed to a new Eppendorf and 2 µL was used for standard PCR using the Super-
Therm Taq polymerase and the primers detailed below (Table 5). The cycling conditions used were as 
follows 95°C for 4 min followed by 35 cycles of 95°C for 30 secs, 60°C for 30 secs and 72°C for 1 min and a 
final 72°C for 7 min step. The product was then run on a 2% agarose gel containing SYBR-safe and 
visualised using the G:Box gel documentation system. 
Table 5: Primers for the PCR Validation of Amidase Deficient Mutants/Complement Strains of 
Mycobacterium tuberculosis 
Primer Name Primer Sequence (5’-3’) Primer Length 
(bp) 
TB Ami1 SC F Primer      TGGACCTACGAGTTGGCC 18 
TB Ami1 SC R1 Primer   GCCGAGTAGTTGACGTGGA 19 
TB Ami1 SC R2 Primer   CCCTAGTCCTCGACAACTGC 20 
TB Ami4 SC F Primer AGGCATCCGGAGGTATCC 18 
TB Ami4 SC R1 Primer   CACTCGACGCCAATCATGT 19 
TB Ami4 SC R2 Primer   CCGGTTGACATCGTTGCA 18 
 
2.1.4 Cytokine Analysis via Enzyme-Linked Immunosorbent Assays (ELISA) 
BMDM supernatants were removed from wells and placed in 96-well filter plate (Cornin FiltrEXTM) and 
spun at 1500rpm for 5min at 4°C to remove residual Mtb bacilli.  A 96-well microplate was coated with 50 
µL of primary antibody (IL-12p40, IFN-y, IL-6, CCL2, G-CSF, IL-1α, TNFα, GM-CSF, IL-17, CCL3, TGFβ, IL-10, 
IFN-β, CXCL2, CCL5, CXCL1, CXCL5, CXCL10, IL-1β, IL-4, IL-12p70 and IL-23) and incubated overnight at 4° 
C. The wells were then washed four times with washing buffer (0.02% (w/v) KCL, 0.02% (w/v) KH2HPO4, 
0.15% (w/v) Na2HPO4.2H20, 0.8% (w/v) NaCl and 0.05% (v/v) Tween-20) followed by treatment using 200 
µL of blocking buffer (2% BSA) and incubated at 37° C for 2 hours. A two-fold dilution series of recombinant 
mouse protein was prepared over 12 wells using an initial concentration of 100 ng/mL. Sera from 
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unknown samples were plated in duplicate and 3-fold dilution series of the samples were prepared over 
3 wells. Approximately 50 µL of unknown sera and the diluted standard was then transferred to the 
corresponding wells of the washed ELISA plate and incubated at 4°C overnight. Each well of the washed 
ELISA plate was first treated with 50 μL of secondary biotinylated rat anti-mouse antibody and incubated 
at 37° C for 2-3 hours. Following this incubation, 50 μL of streptavidin-alkaline phosphate (1:100) was 
added and the plate was incubated at 37°C for 1 hour. Finally, 50 μL of 4-nitrophenyl disodium salt- 
hexahydrate (PNP) (0.1 g/mL) was added to each well and the OD405 was measured with Plate Reader 
(SpectraMax ID3) and analysed using the SoftMax programme (V6). 
2.1.5 Histology and Alveolar Space Assessment 
Lungs from mice infected with the amidase mutant, the complemented strain, and wild-type H37Rv were 
isolated and fixed using formalin solution and stained with haematoxylin and eosin as per previously 
published studies [252]. Analysis of lung sections and assessment of alveolar space was performed using 
NIS advanced software on a Nikon (Tokyo, Japan) 90i microscope. Additionally, lung weight index (LWI) 






2.1.6 Flow Cytometry 
Briefly, single-cell suspensions from the lung tissues were prepared by chopping them into small pieces 
followed by incubation in Dulbecco’s Modified Eagle Media (DMEM) containing 0.18 mg/ml Collagenase 
Type I (Sigma, St. Louis, MO), 0.02 mg/ml DNase I (Sigma, St. Louis, MO) for 1 hour at 37°C under constant 
rotation, followed by mechanically passing through a 100 μm and 70 μm cell strainer sequentially. 
Erythrocytes were lysed using red blood cell (RBC) lysis buffer (155 mM NH4Cl, 12 mM NaHCO3, 0·1 mM 
EDTA).A single-cell suspension (1x106 cells) from infected lung tissue was stained for the following surface 
markers suspended in FACs buffer comprising of PBS supplemented with 1% BSA and 0.1% NaN3: CD64 
(Clone X54-5/7 PeCy7, BioLegend), Ly6C (Clone AL-21 PerCPCy5.5, BD Biosciences), CD11b (Clone M1/70 
V450, BD Biosciences), MHCII (Clone M5/114.15.2 AF700, BioLegend), CD103 (Clone M290 PE, BD 
Biosciences), CD11c (Clone HL3 APC, BD Biosciences), SiglecF (Clone E5-2440 APC-Cy7, BD Biosciences), 
Ly6G (Clone 1A8 FITC, BD Biosciences), F4/80 (Clone BM8 PeCy7, eBiosciences), CD4 (Clone RM4-5 BV510, 
BD Biosciences), CD44 (Clone IM7 PE, BD Biosciences), CD3 (Clone 500A2 AF700, BD Biosciences), CD62L 
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(Clone MEL-14 V450, BD Biosciences), CD19 (Clone 1D3 PerCPCy5.5, BD Biosciences) and CD8 (Clone 53-
6.7 APC, BD Biosciences). The acquisition of samples was conducted using BD LSR Fortessa, and data 
analysis was performed with FlowJo v10 software (Treestar, Ashland, OR, US). 
2.1.7 Statistical Analysis 
All experimental data were analysed using Graph-Pad Prism 8.0.2, one-way ANOVA was used. A *p-value 
of less 0.05 was considered significant, with *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 n=3-
6. Sample size determined using G*Power (version 3.19.7). Optimally, a total sample size of 18 (n=6 per 
group) with an expected effect size (f=1.5) and an α=0.5 allowed for a statistical power of 99%. 





4 Chapter Three 
Loss of putative amidases in Mycobacterium tuberculosis does not affect the 
ability to colonize macrophages and mice 
 
4.1 Introduction 
Tuberculosis (TB) causes the largest number of human deaths attributable to a single human pathogen 
[21]. It is estimated that globally 1 in 4 people are infected with Mycobacterium tuberculosis (Mtb), the 
causative agent of TB [21]. The rapid emergence of drug-resistant TB and the continued failure to create 
a universally efficacious vaccine have highlighted the need for new effective therapies. The discovery and 
characterization of novel gene targets for therapeutic intervention thus remain a key area of TB research. 
The biosynthesis of the bacterial cell wall and remodelling of the complex macromolecules which 
comprise it are essential processes under strict regulatory control to facilitate normal cell division, growth, 
virulence, as well as resistance to antibiotics [100-102]. This dynamic balance of cell wall biogenesis vs. 
degradation is achieved via the coordinated action of multiple enzymes and dysregulation thereof has 
deleterious implications for the mycobacterial cell, an effect that can potentially inform novel drug design 
[141, 173, 254, 255]. In the past, such a strategy has served as the basis for the successful development 
of many commercial antibiotics and similar approaches may be beneficial for TB [256]. 
Peptidoglycan (PG) is unique to the bacterial cell wall and is essential for the maintenance of cytoplasmic 
turgor and cell morphology. PG is made up of crosslinked N‑acetylglucosamine (NAG) and 
N‑acetylmuramic acid (MurNAc or NAM), which are potent bacterial antigens that are detected by 
multiple host pattern recognition receptors (PRR) during infection [153]. Four PG recognition proteins 
(PGLYRP1-4), which directly bind to the PG of the cell wall have been identified in mammals. This detection 
is facilitated via recognition of the muramyl pentapeptide or tetrapeptide present on the bacterial cell 
wall and has been shown to elicit antibacterial activity [154]. Cytosolic nucleotide-binding oligomerization 
domain-containing protein 1 (NOD1) and nucleotide-binding oligomerization domain-containing protein 
2 (NOD2) are the two most well-understood sensors of PG [153]. NOD1 identifies PG through the binding 
of the muropeptide γ-d-glutamyl-meso-diaminopimelic acid (iE‑DAP) [155, 156]. NOD2 identifies PG via 
muramyl dipeptide (MDP), which is formed via the acetylation of MurNAc [157, 158]. The binding of these 
ligands to either NOD1 or NOD2 respectively ultimately results in the activation of two pathways, namely; 
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the inhibitor of nuclear factor-κB (IKK) complex leading to activation of nuclear factor-κB (NF‑κB), or 
activation of transforming growth factor beta-activated kinase 1 (TAK1) and the mitogen-activated protein 
kinase (MAPK) signalling cascade [160]. Both of these pathways initiate the production of inflammatory 
cytokines and chemokines which are essential for the host immune response and antigen presentation 
[160]. Additionally, NOD-, leucine-rich repeat receptor (LRR-) and pyrin domain-containing 3 (NLRP3) have 
also been implicated in the sensing of PG [164], whereas the role of toll-like receptors (TLR) in PG 
recognition remains controversial.  
Bacteria have evolved several strategies to subvert immune detection to elicit chronic infection and 
prolonged survival. Often, this is facilitated via the remodelling of the PG sacculus. Previous studies in 
model pathogenic bacterial species have demonstrated that these organisms can evade the host immune 
system and enhance their pathogenicity through the deacetylation or the acetylation of the PG sugar 
backbone via the genes, pdgA and O‑acetyltransferase, respectively. [161-163]. More specifically, the 
deacetylation of NAG or MurNAc has been shown to abrogate NOD1/2 and inflammasome activation 
[164]. Additionally, Mtb can evade the NOD1 host immune response via the amidation of the meso–
diaminopimelic acid (mDAP), thus removing the substrate required for the formation of iE-DAP, the ligand 
of NOD1 [127, 165]. 
During growth and division, PG is remodelled via the action of several remodelling enzymes such as 
transpeptidases, endopeptidases, carboxypeptidases, amidases, and transglycosylases [84, 141, 257]. 
These enzymes have important roles in the hydrolysis, synthesis, crosslinking and remodelling of the PG 
sacculus and also mediate repair of damaged cell wall material [84, 88]. In this study, we have investigated 
the role of two N-acetylmuramoyl-L-alanine amidases (Ami1 and Ami4) in Mtb. This class of enzymes is 
important for PG degradation during cell division, PG recycling and the homeostatic regulation of osmotic 
pressure via the hydrolysis of the bond between the glycan strand and stem peptide [88]. In Escherichia 
coli, the deletion of several amidases resulted in arrested cell separation after cytokinesis leading to the 
formation of bacterial chains and altered antibiotic susceptibility [137]. The role of amidases in Mtb 
requires further work. The crystal structure of Rv3717 (herein referred to as Ami1), a mycobacterial 
amidase has been solved and bears structural similarity to amidase_3 domain-containing amidases 
observed in E. coli, with demonstrated ability to cleave PG [171, 172]. Whilst lacking efficient hydrolase 
activity relative to Ami1, Ami2 is essential in regulating cell growth via phospho-relay mechanisms [258, 
259]. In addition to Ami1 and Ami2, two more amidase-2-domain containing amidases have been 
identified in Mtb, designated Ami3 (Rv3811) and Ami4 (Rv3594) [98]. In Mycobacterium smegmatis, Ami3 
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is stabilized by mannosylation and subject to degradation by the HtrA protease as dysregulated levels of 
this protein resulted in cell death. Ami1 deletion in M. smegmatis was found to confer dysfunctional 
septation, resulting in the formation of cellular chains, with a two-to-four-fold increase in susceptibility to 
a range of cell wall targeting antimicrobial agents [174].  
In Mtb, an Ami1 deficient mutant is defective for survival in chronic infection in mice where Ami1 appears 
to play a synergistic role with RipA, another cell wall endopeptidase in mediating survival and tolerance 
[99]. In this study, we further investigate host immune responses in murine macrophages and mice 
infection with Ami1 and Ami4 defective mutants and assess the changes in antibiotic susceptibility that 
may occur upon deletion of amidases in Mtb.
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4.2 Methods and Materials 
4.2.1 Mice 
8-12 weeks age, male wild-type C57BL/6 mice (Jackson Labs) were utilized for all mouse infection studies as 
well as the generation of bone-marrow-derived macrophages for this study. Following infection, mice were 
housed in a biosafety level 3 containment facility, maximum six per individually ventilated cage with filter tops 
(type 2 long), as well as dried wood shavings and shredded filter paper as floor coverings. The temperature 
range was set at 22 to 24 °C and 12-to-12-hour light cycles. 
4.2.2 Ethical Statement 
All experiments were conducted this study were done in accordance with the Animal Research Ethics 
Committee of South African National Standard (SANS 10386:2008) and the University of Cape Town, South 
Africa for practice on animal procedures. The protocol (Permit number: AEC 015/40 and AEC 015/36) was 
approved by the Animal Ethics Committee, Faculty of Health Sciences, University of Cape Town (Cape Town, 
South Africa).  
4.2.3 Generation of BMDMs 
The generation of murine bone marrow-derived macrophages was achieved through the extraction and 
subsequent differentiation and polarisation of murine pluripotent stem cells as previously described [41]. Post 
differentiation, BMDM were cultured in standard DMEM medium supplemented with 10% fetal calf serum 
(FCS) at 37°C. Cells were adhered over 12 -24 hours in 96-well plates (Nunc, Denmark) at a concentration of 2 
x 105 cells per well. Post adherence, the cell media was supplemented with 100 U/mL recombinant IFN -γ (BD 
Biosciences) for 24 hours. Cells were infected with Mtb strains at a multiplicity of infection (MOI) of 1 for 
indicated time points.   
4.2.4 Mycobacterium tuberculosis Strains and CFU Analysis 
The Mtb deletion mutants (Δami1, Δami4) and complemented strains (Δami1::ami1, Δami4:: ami4) were 
constructed by Dr Sibusiso Senzani and Dr Melissa Dalcina Chengalroyen (DST/NRF Centre of Excellence for 
Biomedical TB Research, Faculty of Health Sciences, University of the Witwatersrand, National Health 
Laboratory Service, Johannesburg, 2001, South Africa) from wild-type H37Rv (ATCC 25618) as described 
previously (Table S1 and S2). Cells were cultured at 37°C in 7H9 medium supplemented with 10% Middlebrook 
OADC Growth Supplement OADC and glycerol (1%) to at OD of ~0.6. To ensure single-cell stocks, the Mtb 
culture was vortexed vigorously using sterile glass beads. The culture was then centrifuged at 700 rpm for 5 
min. The upper clump-free volume was removed to a new tube and stored at -80°C in 15% glycerol. To 
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determine CFU, infected cells were lysed in 10% Triton X-100 (Sigma) and the cell lysate was plated on 7H11 
agar supplemented with 10% Middlebrook OADC Growth Supplement and 0.5% glycerol. Plates were cultured 
for 2 -3 weeks at 37°C. 
 
4.2.5 Genotyping and Confirmation of Amidase deletion 
Mycobacterium tuberculosis amidase deficient mutant strains were assessed via polymerase chain reaction 
(PCR). Mycobacterium stocks were streaked on 7H11 agar plates and incubated at 37˚C for 4 weeks. A single 
colony was then picked and inoculated in 50 µL sdH2O and heat-inactivated at 95°C for 10 min. 25 µL 
chloroform was added, and the solution was centrifuged at maximum speed for 10 minutes. The top layer was 
used for standard PCR. The primers used for verification of the genotypes were as follows Ami1 SC F 5’- 
TGGACCTACGAGTTGGCC-3’, Ami1 SC R1 5’- GCCGAGTAGTTGACGTGGA-3’, Ami1 SC R2 5’- 
CCCTAGTCCTCGACAACTGC-3’, Ami4 SC F 5’- AGGCATCCGGAGGTATCC-3’, Ami4 SC R1 5’- 
CACTCGACGCCAATCATGT-3’ and Ami4 SC R2 5’- CCGGTTGACATCGTTGCA-3’. The cycling conditions are as 
follows 95°C for 4 min followed by 35 cycles of 95°C for 30 secs, 60°C for 30 secs and 72°C for 1 min and a final 
72°C for 7 min step. The PCR product was then run on a 2% agarose gel containing SYBR-safe and visualised 
using the G.Box (Syngene) and Genesnap (Syngene). 
4.2.6 In vivo Mtb infection and CFU analysis 
Anaesthetized C57BL/6 mice were infected intranasally with approximately 100-CFU in sterile saline. Infected 
mouse lungs were homogenised to produce a single-cell suspension. To determine lung CFU at 3- weeks and 
6-weeks post-infection and to determine bacilli uptake at 1-day post-infection, whole lung homogenates were 
plated on 7H11 agar plates containing 10% OADC and 0.5% glycerol for 2–3 weeks.  
 
4.2.7 In vitro / in vivo Antibiotic Sensitivity Assessment 
AlamarBlue: Antibiotic sensitivity testing was performed in clear 96-well plates (Nunc). The outermost wells 
were filled with sterile, distilled water to prevent dehydration from the sample wells. Initial drug 
concentrations were made up in sterile, distilled water; Meropenem (8 ug/mL), pyrazinamide (400 ug/mL), 
isoniazid (0.2 ug/mL) and rifampicin (0.2 ug/mL) (Sigma). The drug was then diluted two-fold in 7H9 in the 96-
well plate. Approximately, 1x105 CFU was added per well. The drug only, media only, and Mtb only controls 
were included on each plate. The plates were incubated at 37°C for 14-days. On day 14, 20 uL AlamarBlue™ 
was added to all wells and the plates were incubated overnight. The microwell plates were read at an 
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absorbance of 570 nm or fluorescence of 585/610 nm using a Spectromax i3X (Molecular Devices) plate 
reader. Mean fluorescence was calculated from triplicate wells. 
BMDM Antibiotic Assay: BMDMs were generated as above. 2 x105 cells were plated in a clear 96 well plate and 
rested for 12 hours. Cells were then infected with Δami1, Δami4, Δami1::ami1, Δami4:: ami4, and H37Rv at an 
MOI of 1. All mutant strains were transformed to express constitutive mCherry. At 4-hours post-infection, drug 
dilution was carried out as above. Plates were read at 8 days post-infection. Fluorescence was read the 
excitation wavelength of 585 and emission wavelength 610.  
In vivo antibiotic sensitivity assessment: C57/BL6 were infected intranasally with 100-CFU. Infection was 
allowed to progress for 2 weeks, before the initiation of drug treatment comprising of isoniazid (100mg/L) in 
the drinking water for a further 2 weeks as previously published[260]. CFU were analysed at 0-, 2-, 4- and 6-
WPI as described above. 
4.2.8 Flow Cytometry 
Briefly, single-cell suspensions from the lung tissues were prepared by chopping them into small pieces 
followed by incubation in Dulbecco’s Modified Eagle Media (DMEM) containing 0.18 mg/ml Collagenase  Type 
I (Sigma, St. Louis, MO), 0.02 mg/ml DNase I (Sigma, St. Louis, MO) for 1 hour at 37°C under constant rotation, 
followed by mechanically passing through a 100 μm and 70 μm cell strainer sequentially. Erythrocytes were 
lysed using red blood cell (RBC) lysis buffer (155 mM NH4Cl, 12 mM NaHCO3, 0·1 mM EDTA).A single-cell 
suspension (1x106 cells) from infected lung tissue was stained for the following surface markers suspended in 
FACs buffer comprising of PBS supplemented with 1% BSA and 0.1% NaN 3: CD64 (Clone X54-5/7 PeCy7, 
BioLegend), Ly6C (Clone AL-21 PerCPCy5.5, BD Biosciences), CD11b (Clone M1/70 V450, BD Biosciences), 
MHCII (Clone M5/114.15.2 AF700, BioLegend), CD103 (Clone M290 PE, BD Biosciences), CD11c (Clone HL3 
APC, BD Biosciences), SiglecF (Clone E5-2440 APC-Cy7, BD Biosciences), Ly6G (Clone 1A8 FITC, BD Biosciences), 
F4/80 (Clone BM8 PeCy7, eBiosciences), CD4 (Clone RM4-5 BV510, BD Biosciences), CD44 (Clone IM7 PE, BD 
Biosciences), CD3 (Clone 500A2 AF700, BD Biosciences), CD62L (Clone MEL-14 V450, BD Biosciences), CD19 
(Clone 1D3 PerCPCy5.5, BD Biosciences) and CD8 (Clone 53-6.7 APC, BD Biosciences). The acquisition of 
samples was conducted using BD LSR Fortessa, and data analysis was performed with FlowJo v10 software 
(Treestar, Ashland, OR, US) using the gating strategies detailed in the supplementary figures (Supp. Fig. 1 and 
2). 
 
4.2.9 Histology and Alveolar Space Assessment 
Lungs from mice infected with the amidase mutant, the complemented strain, and wild-type H37Rv were 
isolated and fixed using formalin solution and stained with haematoxylin and eosin as per previously published 
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studies [252]. Analysis of lung sections and assessment of alveolar space was performed using NIS advanced 
software on a Nikon (Tokyo, Japan) 90i microscope. Additionally, lung weight index (LWI) was utilised as a 






4.2.10 The enzyme-linked immunosorbent assay 
The supernatant extracted from the whole lung homogenate was isolated from infected murine lungs via 
centrifugation. Filtered supernatant was used to detect IL-12p40, IL-12p70, IFN-γ, IL-6, CCL2, GM-CSF, TGFβ, 
IL-4 (BD Biosciences), G-CSF, CXCL2, CCL3, CCL5, CXCL1, CXCL5, CXCL10, IL-1β (R&D Scientific) IL-1α, TNF, IL-
17, IL-10, IFNβ, and IL-23 (BioLegend) via the enzyme-linked immunosorbent assay (ELISA) according to 
manufacturer suggested dilutions. Chemokine and cytokine protein expression was measured using SoftMax 
Pro 6. 
4.2.11 Statistical Analysis 
All experimental data were analysed using Graph-Pad Prism 8.0.2, one-way ANOVA was used. A *p-value of 
less 0.05 was considered significant, with *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001 n=3-6. Sample 
size determined using G*Power (version 3.19.7). Optimally, a total sample size of 18 (n=6 per group) with an 
expected effect size (f=1.5) and an α=0.5 allowed for a statistical power of 99%. Alternatively, a minimum 
sample size of 9 (n=3 per group) allowed for 87% should mice be limiting (Supp. Fig 4). 
 
4.3 Results 
Genomic maps of Mtb amidase knockout Mtb strains 
The genomic map of the relevant locus is shown for the H37Δami1 strain, H37Δami4 and the wild-type H37Rv 
strains below (Fig. 17a-b). Also shown on the left is the PCR confirmation of the genotype and Southern 
blotting is shown on the right. For PCR confirmation of Ami1 and Ami4, chromosomal DNA was used to amplify 
the Ami1 alleles from the wild type and mutant strains using the primers described in Table S1 and indicated 
as red arrows above. The expected sizes of the amplicons are as follows: Ami1:1526 bp and Δami1: 580 bp; 
ami4, 1711 bp and Δami4, 460 bp. For the Southern blot analysis, chromosomal DNA from the parental and 




Figure 17: Genotypic analysis of the amidase Mb strains by PCR and Southern blot analysis. A) The genomic 
map of the relevant locus is shown for the A) H37Δami1 strain B) H37Δami4 strain and the wild-type H37Rv 
strain. The probe used for hybridisation is shown as a solid green box and the expected sizes are indicated by 
the blue arrows. The figures are not drawn to scale. All mutant strains generated for this study and the figure 
above were created by Dr Sibusiso Senzani and Dr Melissa Dalcina Chengalroyen, DST/NRF Centre of 
Excellence for Biomedical TB Research, Faculty of Health Sciences, University of the Witwatersrand, National 
Health Laboratory Service, Johannesburg, 2001, South Africa. 
 
Genotypic Validation of Amidase Mutant Strains Post Culture 
Bulk experimental stocks of the amidase mutants (Δami1 and Δami4), their complements (Δami1::ami1 and 
Δami4::ami4) and wild-type, H37Rv were generated from single culture aliquots in liquid broth. Previous, work 
showed that there was no difference in the growth rate observed between strains (Supp. Fig. 3). Post liquid 
culture, the fidelity of the mycobacterial strains was assessed to ensure the knockouts where still 
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phenotypically distinct from the complement and WT strains. To assess this, the Mtb strains were cultured on 
agarose gel plates for approximately two weeks. Subsequently, colonies were picked and lysed to extract the 
bacterial DNA. Via PCR, the genotypes of the mycobacterial strains to be used in this study were then verified 
(Fig. 18). For the Ami1 mutant (Fig. 18a), the knock-out possessed a single band which was approximately 750 
bp large. The complemented strain possessed the expected two bands which corresponded to approximately 
650 bp and 400 bp in size, respectively. Lastly, the wildtype strain possesses a single 400 bp band. Similarly, 
the Ami4 (Fig. 18b) mutant strain possessed a single band which was approximately 300 bp in size. The 
complemented strain had two bands which were approximately 300 bp and 400 bp in size. The wildtype 
amplicon was approximately 400 bp in size.  
 
Figure 18: Genotypic validation of experimental strains utilised in this study post high-throughput culture. 
A) Ami1 and B) Ami4 mutant strains, their respective complemented strains (Δami1::ami1 and Δami4::ami4)  
and the wild-type control, H37Rv, post stock culture. 
 
Mtb Amidase 1 and 4 deletion mutants induce an elevated proinflammatory response in macrophages 
Mutants defective for the Ami1 and Ami4 genes were generated using two-step allelic exchange mutagenesis 
and genotyped by PCR and Southern blot (Fig. 17a-b and Fig. 18a-b). To evaluate if Mtb amidases regulate host 
immune responses, the Δami1 and Δami4 mutants were assessed for cytokine and chemokine production in 
macrophages following infection. Using Cell Titer Blue assay, we observed that the cell viability of murine bone 
marrow-derived macrophages (BMDM) was not affected following infection with either Δami1 and Δami4 
mutants when compared to the wild-type Mtb H37Rv and genetically complemented strains (Fig. 19a-b). 
Furthermore, both mutants were equally sensitive to the IFNγ-induced antimicrobial activity of BMDMs 
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relative to the wild-type and Δami1 complemented strain as measured by classical colony-forming unit (CFU) 
enumerations (Fig. 19c-d). The Δami1 mutant infection in BMDMs induced a prominently proinflammatory 
cytokine response through increased secretion of IL-1α, IL-6, and IL-12p40 (Fig. 20a). In addition, the CCL2 
chemokine, responsible for monocyte recruitment [261], was significantly increased in the Mtb Δami1 mutant 
infection when compared to the wild type or genetically complemented strains (Fig. 20a). Similarly, infection 
of BMDMs with the Mtb Δami4 mutant resulted in significantly increased production of IL-1α, IL-1β, IL-6, and 
IL-12p40 (Fig. 20b). Together, these results demonstrate that Ami1 and Ami4 are dispensable for growth in 
macrophages. However, the deletion of either Mtb amidases can induce increased proinflammatory cytokine 
and chemokine responses during macrophage infection.   
 
 
Figure 19: Mtb infection of macrophages with the Δami1 and Δami4 mutant has no effect on macrophage 
cell viability and intracellular Mtb growth. A, B) Cell viability of BMDM infected with the Ami mutants (Δami1 
and Δami4), complemented strains (Δami1::ami1 and Δami4::ami4) and wild-type H37Rv was measured via 
Cell Titer Blue at 0 (4 hours), 2, 4 and 6-days post-infection. C, D) CFU counts of BMDMs infected with the Ami 
mutants (Δami1 and Δami4), complemented strains (Δami1::ami1 and Δami4::ami4) and wild-type H37Rv at 
0 (4 hours), 2, 4 and 6-days post-infection  (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001, one-way 




Figure 20: Mtb infection of macrophages with the Δami1 and Δami4 mutant induces a heightened 
proinflammatory response. At 4- and 6-days post-infection, the proinflammatory cytokine and chemokine 
production of infected macrophages was measured via ELISA using A) Δami1, Δami1::ami1 and Δami1::ami1 
and H37RV and B) Δami4, Δami4::ami4 and H37RV. * = Δami1/4 vs. WT, # = complemented strains vs. WT (*/#P 




Figure 21: Infection of mice with the Δami1 mutant displays immune response at 3-WPI which is absent at 
6-WPI. C57BL/6 male mice were infected intranasally with 100-CFU of the Mtb Δami1 mutant, complemented 
Δami1::ami1 and WT, H37Rv. At 3-WPI infected mice were sacrificed and the lungs were collected to quantify 
A) Cytokine and chemokine levels from whole lung homogenate of Mtb-infected mice were measured by ELISA 
B) H&E histology staining of Mtb-infected lungs at 3-WPI. Inflammation was quantified as a measure of 
alveolar space. Scale bars = 1000 µm C, D) At 3- and 6-WPI infected mice were sacrificed to measure 
mycobacterial burden by CFU enumeration in the lungs and spleen(*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P 




Mtb Ami1 knockout results in a heightened acute immune response which is subsequently lost during 
chronic phase infection in mice 
To investigate if the elevated pro-inflammatory responses elicited by the amidase 1 and 4 deletion Mtb 
mutants during macrophage infection translate to elevated immune responses in vivo, we infected C57BL/6 
mice intranasally with the Mtb Δami1 or Δami4 mutant strains. In the acute phase, at 3-weeks post-infection 
(WPI), the Δami1 mutants significantly increased the production of several proinflammatory cytokines (IFNγ 
and TNF), type 1 interferon (IFNβ), regulatory cytokines (TGFβ and IL-10), and chemokines (CCL2, CCL3, CXCL1, 
CXCL5, and CXCL10) in whole lung homogenates when compared to the Δami1 complemented and WT H37Rv 
Mtb strains (Fig. 21a). Interestingly, Mtb Δami1 mutants displayed reduced pulmonary histopathology, as 
measured by percentage alveolar spaces relative to the Δami1 complemented and WT H37Rv Mtb strain (Fig. 
21b). Despite the increased inflammatory cytokine and chemokine responses at 3-WPI, the mycobacterial 
growth rates of Δami1 in the lungs and the spleen were similar to the Δami1 complemented and WT H37Rv 
Mtb strains as measured by classical CFU enumerations at 3- and 6-weeks post-infection (Fig. 21c and d). Using 
flow cytometry, we measured numerous immune cell populations in the lungs at 3-weeks post-infection and 
determined that Mtb Δami1 infection significantly exhibited decreased percentage of alveolar macrophages, 
CD11b DCs, neutrophils and monocytes (Fig. 22a) with a concomitant decrease in total CD4 cells, CD8 cells, 
effector CD4+ as well as naïve, effector and memory CD8+ T cells (Fig. 22c) when compared to WT Mtb. Within 
the mediastinal lymph node (LN), at 3-WPI, Mtb Δami1 mutant infection resulted in an increased frequency of 
B cells (Fig. 23a). However, when calculated for total cell numbers within the lung and mediastinal lymph node, 
no measurable difference in cellular recruitment was observed between the groups (Fig. 22b, d and 23b). At 
6-weeks post-infection, the percentages and numbers of cell populations (Fig. 25a-d, 26a,b), cytokine and 
chemokine expression, histopathology and percentage of alveolar spaces (Fig. 24a-c) were similar between 






Figure 22: At 3-WPI, Δami1 mutant infection in mice reduces specific myeloid and lymphoid cell populations 
in the lung. C57BL/6 male mice were infected intranasally with 100 CFU of Δami1 mutants, Δami1::ami1 and 
wild-type H37Rv. Infected mice were sacrificed at 3-WPI and lungs were collected to measure the frequency 
and cell numbers of A, B) myeloid and C, D) lymphoid cell populations. Cell surface markers used: Alveolar 
Mph (Alv MΦ) = SiglecF+CD11c+, recruited Mph (Rec MΦ) = CD11c+ SiglecF-, CD103 DCs = 
MHCII+CD11c+CD103+CD11b-, CD11b DCs = MHCII+CD11c+CD103+CD11b+, neutrophils (Nφ) = LY6G+CD11b+, 
MoMs = CD11b+CD11c+, EOS = SiglecF+CD11b+, B cells = CD19+CD3-, CD8+ T cells = CD3+CD4-CD8+, CD4+ T cells 
= CD3+CD4+CD8-, Naïve T cells = CD62L+CD44+, Memory = CD62L+CD44- Effector = CD62L-CD44+(**P ≤ 0.01, 




Figure 23: At 3-WPI, Δami1 mutant infection in mice recruits B cells in the mediastinal lymph node. C57BL/6 
male mice were infected intranasally with 100 CFU of Δami1 mutants, Δami1::ami1 and wild-type H37Rv. 
Infected mice were sacrificed at 3-WPI. A, B) The mediastinal lymph nodes were collected to determine the 
frequency and cell numbers of lymphoid populations. Cell surface markers used: B cells = CD19+CD3-, CD8+ T 
cells = CD3+CD4-CD8+, CD4+ T cells = CD3+CD4+CD8-, Naïve T cells = CD62L+CD44+, Memory = CD62L+CD44- 





Figure 24: At 6-WPI, Δami1 mutant infection in mice induces similar inflammation in mice relative to wild-
type. Infected male mice were sacrificed at 6-WPI and the lungs were collected to quantify the A) Cytokine 
and chemokine levels from whole lung homogenate of Mtb-infected mice were measured by ELISA. B) Lung 
inflammation at 6-WPI was quantified as a measure of alveolar space from C) H&E-stained infected lungs. 





Figure 25: At 6-WPI, Ami1 deletion induces similar myeloid cell populations in the lung. C57BL/6 male mice 
were infected intranasally with 100 CFU of Δami1 mutants, Δami1::ami1 and wild-type H37Rv. Infected mice 
were sacrificed at 6-WPI and lungs were collected to measure the frequency and cell numbers of A, B) myeloid 
and C, D) lymphoid cell populations. Alveolar Mph (Alv MΦ) = SiglecF+CD11c+, recruited Mph (Rec MΦ) = 
CD11c+ SiglecF-, CD103 DCs = MHCII+CD11c+CD103+CD11b-, CD11b DCs = MHCII+CD11c+CD103+CD11b+, 
neutrophils (Nφ) = LY6G+CD11b+, MoMs = CD11b+CD11c+, EOS = SiglecF+CD11b+, B cells = CD19+CD3-, CD8+ T 
cells = CD3+CD4-CD8+, CD4+ T cells = CD3+CD4+CD8-, Naïve T cells = CD62L+CD44+, Memory = CD62L+CD44- 




Figure 26: At 6-WPI, Ami1 deletion results in marginally decreased lymphoid cells within the mediastinal 
lymph node. C57BL/6 male mice were infected intranasally with 100 CFU of Δami1 mutants, Δami1::ami1 and 
wild-type H37Rv. Infected mice were sacrificed at 6-WPI. A, B) Mediastinal lymph nodes were collected to 
determine the frequency and cell numbers of lymphoid populations. B cells = CD19+CD3-, CD8 T cells = 
CD3+CD4-CD8+, CD4 T cells = CD3+CD4+CD8-, Naïve T cells = CD62L+CD44+, Memory = CD62L+CD44- Effector = 
CD62L-CD44+ (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, one-way ANOVA, n=5-6). 
 
Ami4 deletion does not affect the host immune response during acute and chronic Mtb infection  
We further investigated the acute and chronic host immune response to Mtb Ami4 deficiency using the Δami4 
mutants. The bacterial burden (Fig. 27a), inflammation assessed by histopathology (Fig. 27b) and 
cytokine/chemokine expression (Fig. 27c-d) were similar between all groups. In the lung, at 3-WPI, Ami4 
deletion elicited decreased percentages of alveolar macrophages, CD11b DCs, CD103 DCs, monocytes and 
eosinophils (Fig. 28a). Additionally, within the lung, a reduction in CD8+, B cells, naïve & memory CD4+, as well 
as reduction in naïve CD8+T cells, was overserved when compared to WT Mtb (Fig. 28a and c). Further, within 
the lymph node at 3-WPI, Ami4 deletion elicited decreased naïve and memory CD4+- and CD8+T cells by 
percentages when compared to WT Mtb (Fig. 29a). However, when calculated for total cell numbers within 
the lung and mediastinal lymph node, no measurable difference in cellular recruitment was observed between 
the groups.  At 6-WPI, within the lung, Ami4 deletion elicited decreased alveolar macrophages, memory CD4+ 
and CD8+ T cells with a concomitant increase in total CD4+-, CD8+ T cells and naïve CD4+T cells and effector 
CD8+ T cells by percentage when compared to WT Mtb (Fig. 30a and c). Within the lymph node, Ami4 deletion 
elicited increased effector CD4+T cells by percentages when compared to WT Mtb (Fig 31e). However, when 
calculated for total cell numbers within the lung and mediastinal lymph node, no measurable difference in 
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cellular recruitment was observed between the groups, except for reduced memory CD4+- and CD8+T cells. 
Together, these data imply that whilst Mtb Ami1 is more immunomodulatory relative to Ami4, the deletion of 
either gene can slightly alter cellular recruitment in lung and lymph node but is, ultimately, insufficient to 





Figure 27: Mtb Ami4 is dispensable for the modulation of the host immune response during acute and chronic 
phase infection in mice. C57BL/6 male mice were infected intranasally with 100 CFU of the Δami4 mutant, 
Δami4::ami4 and H37Rv. A) Infected mice were sacrificed at 3- and 6-WPI to measure mycobacterial burden 
by CFU enumeration in the lungs and spleen. B) General inflammation in the lung was assessed via the lung-
weight index. Cytokine and chemokine levels from whole lung homogenate of Mtb-infected mice were 





Figure 28: At 3-WPI, Δami4 mutant infection in mice reduces specific cell populations within the lung. C57BL/6 male  
mice were infected intranasally with 100 CFU of the Δami4 mutant, Δami4:: ami4 and wild-type H37Rv. Infected mice 
were sacrificed at 6-WPI and lungs were collected to measure the frequency and cell numbers of A, B) myeloid and C, D)  
lymphoid cell populations. Alveolar Mph (Alv MΦ) = SiglecF+CD11c+, recruited Mph (Rec MΦ) = CD11c+ SiglecF-, 
CD103 DCs = MHCII+CD11c+CD103+CD11b-, CD11b DCs = MHCII+CD11c+CD103+CD11b+, neutrophils (Nφ) = 
LY6G+CD11b+, MoMs = CD11b+CD11c+, EOS = SiglecF+CD11b+, B cells = CD19+CD3-, CD8+ T cells = CD3+CD4-CD8+, 
CD4+ T cells = CD3+CD4+CD8-, Naïve T cells = CD62L+CD44+, Memory = CD62L+CD44- Effector = CD62L-CD44+(**P 





Figure 29: At 3-WPI, Δami4 mutant infection in mice reduces specific cell populations within the mediastinal 
lymph node. Infected male mice were sacrificed at 3-WPI and the mediastinal lymph nodes were collected to 
determine the A, frequency and B) cell numbers of lymphoid populations. B cells = CD19+CD3-, CD8 T cells = 
CD3+CD4-CD8+, CD4+ T cells = CD3+CD4+CD8-, Naïve T cells = CD62L+CD44+, Memory = CD62L+CD44- Effector = 




Figure 30: At 6-WPI, Δami4 mutant infection in mice induces lymphoid cells within the lung. C57BL/6 male mice were 
infected intranasally with 100 CFU of the Δami4 mutant, Δami4::ami4 and wild-type H37Rv. Infected mice were sacrificed 
at 6-WPI and the lungs were collected to measure the frequency and cell numbers of A, B) myeloid and C, D) lymphoid 
cell populations. E, F) Mediastinal lymph nodes were collected to determine the frequency and cell numbers of lymphoid 
populations. Alveolar Mph (Alv MΦ) = SiglecF+CD11c+, recruited Mph (Rec MΦ) = CD11c+ SiglecF-, CD103 DCs = 
MHCII+CD11c+CD103+CD11b-, CD11b DCs = MHCII+CD11c+CD103+CD11b+, neutrophils (Nφ) = LY6G+CD11b+, 
MoMs = CD11b+CD11c+, EOS = SiglecF+CD11b+, B cells = CD19+CD3-, CD8+ T cells = CD3+CD4-CD8+, CD4+ T cells 
= CD3+CD4+CD8-, Naïve T cells = CD62L+CD44+, Memory = CD62L+CD44- Effector = CD62L-CD44+(**P ≤ 0.01, 




Figure 31: At 6-WPI, Δami4 mutant infection in mice induces effector CD4+ T cells within the mediastinal 
lymph node. C57BL/6 male mice were infected intranasally with 100 CFU of the Δami4 mutant, Δami4:: ami4 
and wild-type H37Rv. Infected mice were sacrificed at 6-WPI and the mediastinal lymph nodes were collected 
to quantify the A) frequency and B) cell numbers of lymphoid cells within the mediastinal lymph node. B cells 
= CD19+CD3-, CD8+ T cells = CD3+CD4-CD8+, CD4 T cells = CD3+CD4+CD8-, Naïve T cells = CD62L+CD44+, Memory 
= CD62L+CD44- Effector = CD62L-CD44+ (*P ≤ 0.05, **P ≤ 0.01 one-way ANOVA, n=5-6). 
 
Mtb Ami1 deficiency, but not Ami4, results in an increased sensitivity to anti-TB drugs in liquid culture which 
is abrogated during macrophage infection 
Mycobacterial Ami1 deletion has been shown to confer antibiotic sensitivity to antimycobacterial drugs in M. 
smegmatis and Mtb models [99, 174]. To investigate if Mtb strains deficient in Ami1 and Ami4 alter their 
susceptibility to antibiotics, constitutively mCherry expressing Mtb Δami1 mutants, Mtb Δami1 complemented 
and wild-type Mtb H37Rv were cultured in the presence of the anti-TB drugs isoniazid, rifampicin, meropenem 
and pyrazinamide. Mycobacterial viability was assessed fluorometrically via AlamarBlue within 8-days of liquid 
culture. In line with the previously published results on the antibiotic sensitivity of Ami1 deficient mutant in 
M. smegmatis [174], Mtb Δami1 mutants were found to be sensitive to antibiotic exposure in liquid broth 
culture. Here, the Mtb Δami1 mutants displayed heightened sensitivity to isoniazid and meropenem (Fig. 32a). 
However, within macrophages, Δami1 mutants were found to be equally susceptible to rifampicin and 
isoniazid as when compared to Δami1 complemented and WT H37Rv Mtb strains (Fig. 32b). Further, the Δami4 
Mtb mutants were found to be equally susceptible to all drugs when assessed in liquid culture (Fig. 33). 
Together, these data imply that the presence of Ami1 in Mtb may contribute to a tolerance phenotype to 
isoniazid and meropenem when exposed to antibiotic stress in liquid growth culture, but not during 





Figure 32: Increased sensitivity of Mtb Δami1 mutant to isoniazid and meropenem antibiotics in liquid 
culture. A) The Δami1 mutant, Δami1::ami1 and wild-type H37Rv Mtb strains were cultured in 7H9 liquid broth 
culture for 14-days in the presence of isoniazid, rifampicin, meropenem or pyrazinamide.  B) BMDMs were 
infected with a mCherry expressing Δami1 mutant, Δami1: ami1 and wild-type H37Rv Mtb strains. Isoniazid, 
rifampicin, meropenem or pyrazinamide were added 4-hours post-infection and macrophages were culture 





Figure 33: The Mtb Ami4 deletion mutant is equally susceptible to antibiotics in liquid culture. The Δami4 
mutant, Δami4::ami4 and wild-type H37Rv Mtb strains were cultured in 7H9 liquid broth culture for 14-days 
in the presence of isoniazid, rifampicin, meropenem or pyrazinamide  (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, one-
way ANOVA, n=3-4) 
 
Ami1 deficiency increases the resistance of Mtb to isoniazid single treatment in mice 
Previously, increased sensitivity to anti-TB drugs in liquid culture was reported in M. smegmatis Ami1 deleted 
mutants [99, 174] We have also shown that Δami1 Mtb mutants are more susceptible to antibiotic stress in 
liquid media (Fig. 32).  However, the antibiotic susceptibility of amidase mutants in vivo remains to be 
elucidated. To test this, C57BL/6 mice were infected intranasally with Mtb Δami1 mutants, Mtb Δami1 
complemented and wild-type Mtb H37Rv (Fig. 29). At two weeks post-infection, the drinking water was 
supplemented with 0.1g/L isoniazid. The mycobacterial burden in the lungs was assessed before treatment, 
2- and 4-weeks post-treatment. Strikingly, after 2- and 4-weeks of isoniazid treatment, a significantly higher 
number of Mtb Δami1 mutant colonies were observed when compared to Δami1complemented and wild-type 
Mtb H37Rv (Fig. 34). While no wild-type H37Rv colonies were detected following the 4-week course of 
antibiotics treatment (Fig. 34). Together with the axenic culture antibiotic data above (Fig. 32), the effect of 
Ami1 deletion within the in vivo model of infection resulted in a phenotypic reversal where the Ami1 mutants 




Figure 34: Δami1 mutants display increased tolerance to isoniazid treatment in mice. C57BL/6 male mice 
were infected with Δami1 deletion mutants, Δami1::ami1 and H37Rv WT. At 14-days post-infection, Mtb-
infected mice were treated with isoniazid (0.1g/L) in the drinking water for 14-days. A) Mice were sacrificed 
at 2- and 4-weeks post-treatment to measure bacillary counts by CFU enumerations. * = Δami1 vs H37Rv, # = 
Δami1 vs Δami1::ami1 (*P ≤ 0.05, ##P ≤ 0.01****P ≤ 0.0001, one-way ANOVA, n=6). 
 
 
4.4 Discussion  
Cell wall amidases cleave the covalent bonds responsible for the stabilisation of the cell wall sacculus, thus 
represent potential autolytic enzymes that can be targeted for drug therapy. Further, the growth of M. 
smegmatis Ami1 deleted mutant strains in culture media resulted in the release of the mycobacterial cell wall 
material into the extracellular milieu [174]. In line with previous work, this material is probably highly 
antigenic. In the present study, we sought to elucidate the effect of Mtb amidase knockout (Ami1 and Ami4) 
on the host immune response. Despite the similarity of the crystal structure s [171, 172] and genetic 
conservation between multiple species [129], few studies have fully assessed the loss-of-function effects of 
Mtb amidase 1 and 4 in and the host immune response. That these enzymes are so well conserved across 
different kingdoms and domains implies that they may be intrinsic to a common pathway across these varying 
organisms. However, it is also possible that these enzymes may play variable and essential roles in 
mycobacterial ontogeny – especially during stress, such as has been observed in Ami2 [258]. Senzani et al. 
[174] provided evidence in M. smegmatis which revealed that the targeted knockout of Ami1 resulted in 
defective bacterial fission evident through the formation of ectopic lateral buds, the mislocalization of the cell 
elongasome, the bundling of the FtsZ ring and defective septal PG turnover [174]. Further, the authors also 
provided evidence that the Ami1 knockout M. smegmatis mutants experienced approximately 2x higher cell 
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wall permeability and were more sensitive to several antibiotics relative to the wild-type controls. In addition, 
Li [262], provided evidence that Ami1 knockout in M. smegmatis resulted in a defective ability of these 
filamentous mycobacteria to invade human alveolar epithelial cells [262]. In a recent in vivo infection study, 
C57BL/6 mice were infected with Ami1 deficient M. smegmatis mutants. Those authors displayed a diminished 
uptake of the mutants within the lungs, thus confirming the worsened invasion ability of these mutants 
observed in vitro [263]. Besides, the authors observed that the Ami1 deleted mutants induced less 
inflammation despite residing within the lungs twice as long relative to the wild-type and complemented 
strains before being cleared. Interestingly, this finding was verified in the Mtb model where Ami1 was found 
to be important to prolonging chronic Mtb infection [99]. 
These observations are both similar and conflicting to the results acquired in this study. Like the M. smegmatis 
in vivo model, we observed that acute phase Mtb mutant infection resulted in less inflammation by 
immunohistochemistry despite the increased detection of proinflammatory cytokines and chemokines 
relative to the complemented and wild-type strains. However, the uptake of the mutant bacilli and the final 
burden was unchanged relative to the complement and wild-type strains at both acute and chronic stages of 
infection. This implies that the invasion handicap observed in M. smegmatis does not occur in the Mtb model 
of infection. More recently Mtb Ami1 deletion mutants were tested for atypical cell division phenomena. 
Those authors found that under regular culture conditions, Ami1 deletion did not affect the length of daughter 
cells nor the number of division-septa they contained [99].  
M. smegmatis is a fast-growing mycobacterial species that is both sensitive to the host immune response as 
well as being unable to proliferate intracellularly [263]. Conversely, Mtb is a slow-growing mycobacterial 
species, taking 6x longer to divide relative to M. smegmatis. Further, Mtb has been well studied in its ability 
to reside and proliferate intracellularly whilst simultaneously abrogating the antimicrobial host immune 
response through multiple mechanisms [82]. These key differences infer the likelihood of key differences 
observed in Ami1 deletion between Mtb and M. smegmatis models of infection. It is probable that, unlike the 
M. smegmatis model, the induction of filamentation in Mtb is highly stress-dependent and that Ami1 knockout 
may increase the speed to this defective phenotype only after uptake. This may explain why there is no uptake 
impairment within the Mtb model as the bacterial population of Ami mutants vs. the wild-type strain are 
phenotypically homogenous under favourable conditions. The lack of uptake impairment in Ami1-deficient 
Mtb mice within our study has recently been independently verified and further substantiates the hypothesis 
that the host immune effect of amidase deletion may only be detected/exacerbated after successful uptake 
and infection [99].  
Wild-type Mtb bacilli which proliferate intracellularly within the phagosome of macrophages have been 
observed to exhibit filamentous bacterial chains and a dysregulated FtsZ ring phenotype [264]. Interestingly, 
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similar phenotypes have been observed in Salmonella enterica where the authors assessed the role of the 
AmiA and AmiC knockout - conserved orthologues of mycobacterial Ami1 and Ami4 [19]. They provided 
evidence showing that bacilli which were grown under low pH, high osmolarity and sublethal antimicrobial 
stress formed chains of cells that were more sensitive to the host immune response. Within our study, the 
lack of difference in bacterial burden observed between wild-type and amidase-deficient Mtb mutants may 
be attributed to a similar mechanism whereby the host immune milieu within the phagosome induces a 
filamentous phenotype in the wildtype and complemented controls to the same extent of the mutant strains 
at a chronic time point; thus, abrogating the potential deleterious/beneficial effect conferred by Ami1 and 
Ami4 knockout. This line of evidence may explain why we observe an enhanced immune response during the 
acute phase of in vivo infection with Δami1 mutants relative to the control strains which subsequently 
disappears at chronic phase infection. Senzani et al. [174] showed that filamentous Δami1 M. smegmatis 
mutants extruded cell wall material into the cytoplasm during binary fission; this phenomenon may account 
for the enhanced acute immune response observed in vitro and in vivo whilst maintaining the bacterial burden 
in an unknown mycobacterial-specific manner. Previous studies have highlighted the importance of NOD2 in 
the detection and immune response to mycobacterial antigen [265, 266]. Certainly, the increased presence of 
PG muropeptide subunits, in the milieu has the potential to bind to NOD-like receptors and subsequently 
induce an enhanced proinflammatory cytokine response via canonical pathways. This may explain the 
increased pro-inflammatory immune response observed at 3-weeks post-infection, despite the lack of tissue 
inflammation.  
In the present study, we assessed the sensitivity of amidase 1 and 4 knockout Mtb mutants to first -line anti-
TB treatment. Mtb Ami1 knockout mutant bacilli were found to display increased sensitivity to isoniazid and 
meropenem relative to the complemented and wildtype controls (Fig 32a). However, within the cultured 
macrophages, this effect was abrogated (Fig. 32b). The apparent sensitivity of these Mtb Ami1 deletion 
mutants in broth has recently been independently verified [99]. In our study, the high efficacy of INH and RIF 
in cultured macrophages (Fig. 32b) shows that that the drugs can act on internalised Mtb, however, the lack 
of sensitivity observed in the Mtb Δami1 mutant cell-free-bacilli MICs implies an innate host-pathogen 
interaction which neutralises the sensitivity observed in broth. Further, within the C57BL/6 mouse model, Mtb 
Ami1 deletion mutants were observed to be tolerant to INH treatment relative to infective controls at 4-WPI 
(Fig. 34). Further, this observation was significantly exacerbated at 6-WPI. This counter-intuitive phenotype-
reversal which correlates with an increasingly complex host immune response under constant anti-TB drug 
treatments is interesting. From approximately 2-WPI, the adaptive arm of the host immune response is 
activated. Recruited lymphoid cells may contribute to the resistant phenotype observed in the mice infected 
with the mutant strain. At 6-WPI, lung inflammation between the Δami1 mutants, complemented strains and 
the wild-type H37Rv infected mice is the same (Fig. 24a,b) despite a higher frequency of neutrophils and 
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effector CD8 cells within the lung (Fig. 25) of the mice infected with the mutant strain. This observation implies 
that whilst cellular recruitment is largely unchanged by Ami1 deletion, the cells have more of an effector 
phenotype. A similar observation of drug tolerance in the face of increased immune pressure was recently 
reported in 2016 [267]. In that study, the authors found that the tolerance of Mtb to anti-TB treatment was 
altered by the activation status of the myeloid cells isolated from the lungs of Mtb-infected mice. Within our 
study, we observe a heightened immune response at both in vitro (Fig. 20a,b) and at 3-WPI in mice infected 
with the Ami1 deletion mutant (Fig. 21a). Taken together, it may be possible that the increased 
proinflammatory response of the Ami1 deletion mutant and increased tolerance of this mutant to anti-TB 
therapy may be causally linked. The mixed phenotype observed in the complemented strain (Fig. 34) may be 
as of a consequence of the selection of plasmid-free bacilli, thus reverting the complemented stain to the 
knockout phenotype in the absence of hygromycin selection and resulting in increased resistance to INH 
treatment over the long duration of infection. 
Within the phagosome, Mtb bacilli experience multiple stressors which are intended to restrict the growth of 
the pathogen and promote sterilisation; viz, hypoxia, nutrient starvation and ROS stress [268]. In 2016, Boutte 
et al. showed that CwlM, a protein homologous to mycobacterial PG amidases (Ami2) and the major substrate 
of PknB [259], facilitates PG synthesis activity in direct correlation to the nutrient status of the bacilli. During 
nutrient surplus, CwlM is activated via phosphorylation and associates with MurA, an enzyme responsible for 
the formation of the PG network. This association induces MurA’s activity 30-fold and upregulating cell wall 
metabolism. However, under starvation conditions, the phosphorylation of CwlM and the subsequent 
association of CwlM to MurA does not occur resulting in decreased cell wall metabolism and a marked 
tolerance to antibiotics [258]. Ami1 may play a similar role to CwlM in Mtb, however, it is highly unlikely that 
Ami1 alone is responsible for the growth and maintenance of the bacterial PG sacculus.  Further, other amidase 
isoforms may act as a complex to maintain the PG such as Heidrich et al., [137] postulated from his 
observations in E. coli. In nutrient-rich, 7H9 broth and stressor-free conditions, Δami1 mutant bacilli are more 
sensitive to INH and MER indicating possible compensatory mechanisms which may facilitate regular bacterial 
growth and maintenance. However, as nutrients become more limited, the knockout-effect of Ami1 may 
become more pronounced whilst the compensatory mechanism becomes increasingly more inefficient 
resulting in the induction of a tolerant phenotype despite the action of the other mycobacterial amidases.  
One potential limitation of this study is that the immunological effect of Ami deletion was only analysed in 
male C57BL/6 mice. Recent reports have shown that male C57BL/6 mice are slightly more susceptible to Mtb 
infection relative to female mice [269, 270]. This observation has been correlated to secreted cytokine 
differences and B-cell follicle formation in the lung [269, 270]. Whilst sex-differences were not analysed in this 
study, they may further contribute to the immunological effects of Ami deletion reported here. The effect of 
sex should, therefore, be explored further in subsequent future experiments. Additionally, in Fig. 20a, some 
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of the Δami1:ami1 samples induced a higher secretion of pro-inflammatory cytokines than the WT control. It 
is possible that any increase in elicitation of proinflammatory cytokines (IL6, IL12p40 and CCL2) may be as a 
possible artefact of a slightly incorrect MOI. Further, it is possible that without the selective pressure of 
hygromycin, the selection antibiotic under which the complemented strain was maintained in the media, the 
plasmid which allowed for the expression of Ami1, may have been ejected or inhibited. However, as the 
complement and wild-type data are largely in agreement for all subsequent experiments, I believe the 
artefactual dosing hypothesis to be the most likely. 
In conclusion, we provide evidence describing the host immune response, both in vitro and in vivo, to two Mtb 
amidase knockouts; Ami1 and Ami4. Δami1 mutant infection induced a largely pro-inflammatory immune 
response both in vitro and at 3-WPI in vivo relative to WT controls. However, the exacerbated host immune 
response was lost at 6-WPI. Neither Ami1 nor Ami4 deletion resulted in a reduction of bacterial burdens within 
the lung and spleen during acute and chronic phase infection. In vitro antibiotic studies have revealed that 
Δami1 mutants were more sensitive to meropenem and isoniazid, whilst Δami4 mutants were equally 
suspectable to all antibiotics tested. Interestingly, the antibiotic benefit observed under cell-free conditions is 
lost in macrophages and completely reversed in vivo. Future work elucidating this phenomenon as well as 




5 Chapter 4 
The Optimisation and Establishment of a Dual-RNA-Seq Methodology to Detect 




Tuberculosis (TB) has emerged as the world’s most deleterious infectious disease effecting 1-in-4 people [21]. 
The etiological agent of TB, Mycobacterium tuberculosis (Mtb), has evolved the ability to evade the host 
immune response using several strategies [82]. These include the suppression of autophagy [271], 
phagolysosomal maturation [272-274], innate signally pathways [275], antigen processing [276] and the 
countering of host antimicrobial activity [277] among others. Combining these immune evasion strategies with 
the emergence of drug-resistant phenotypes has highlighted the need to better understand Mtb physiology 
and TB pathogenesis. Further, this emphasizes the need to develop novel therapeutic drug strategies that 
either act directly on the pathogen or fortify the host immune response to improve disease outcome. RNA 
sequencing (RNA-seq) is a powerful tool which has allowed researchers to better elucidate unknown cellular 
mechanisms in a range of organisms in a high throughput, robust fashion [278]. Among the most intricate 
interactions which RNA-seq can inform on, is that of between a host and pathogen during infection. During 
infection, a vast number of cellular processes are activated both within the host immune system and within 
the invading pathogen. These complex interactions are made more multifarious by the action of unknown 
genes, RNAs and molecules which may be contributing to immune evasion or sensitivity. Recent studies have 
illustrated that the unbiased interrogation of changing global transcriptional profiles within the host and 
pathogen remains a key method to elucidating these immune events, and may provide key knowledge to 
develop and refine treatment strategies [240]. In vivo dual RNA-seq studies are fraught with technical 
challenges [228]. However, a recent study utilising a dual-RNA seq methodology has been used to successfully 
examine the role of in vivo murine Mtb infection within alveolar and recruited macrophages, linked to 
nutritional immunity [249]. A dual RNA-seq approach is beneficial as it allows for the parallel understanding 
of both transcriptomic changes within the pathogen as well as the host, with both accuracy and depth.  
Further, these processes are almost certainly programmed by underlying genetic changes in both the host and 
pathogen during pathogen challenge and subsequent host immune response. Recently, it has been shown that 
Mtb secretes two proteins (Rv1988 and Rv2966c) which directly acts on the host chromosome and promotes 
bacterial survival [191, 192]. However, many of the specific epigenetic changes that occur during infection and 
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contribute to immune evasion remain unknown. A dual-RNA seq approach has the potential to elucidate the 
mechanisms which occur during host-pathogen interactions. The correlation of transcriptional (RNA-seq data) 
with both epigenetic/histone modification (ChIP-seq) as well as DNA methylation patterns (BS-seq) data allows 
for the formation of strong hypotheses which can then be used to better understand the biology underpinning 
the host-pathogen interaction. Further, this information may elucidate novel gene targets and long non-coding 
RNAs for therapeutic treatment strategies. 
In this study, we provide an optimised proof-of-concept methodology which allows for the extraction of host 
(primary human monocyte-derived-macrophages) RNA, DNA and nuclei whilst simultaneously allowing for the 
enrichment of pathogen (HN878) RNA from the same sample over a longitudinal time course.  We show that 
despite low numbers of Mtb, meaningful RNA-seq data can be acquired. Combining sequence data from 
multiple sources we aim to explore and reconstruct the dynamics of epigenetic and transcriptional 
modifications, their effector proteins in human macrophages following Mtb infection, as well as identify 
associated noncoding RNAs correlated with these epigenetic changes.  
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5.2 Methods and Materials 
5.2.1 Ethics 
This study has been ethically approved for the experimentation with human tissues (MDMs) within the context 
of the research question detailed above (Human ethics protocol: HREC 732/2015). 
5.2.2 Cells and Reagents  
Leuokopaks from healthy donors, standardised for age, sex and race, were acquired from the Western Cape 
Blood Transfusion Service (WCBTS). Standard pathological testing is conducted by the WCBTS on all blood to  
ensure its free from HIV, Hepatitis B and C, and Syphilis. PBMCs are isolated via density centrifugation. 
CD14+CD16+ monocytes were purified via negative selection utilising the MojoSort™ Human Pan Monocyte 
Isolation Kit (Biolegend) and were differentiated into monocyte-derived-macrophages (MDMs) in standard 
RPMI media supplemented with 10% fetal calf serum and 50 ng/uL recombinant human M-CSF over 7-days.  
5.2.3 Mycobacterium tuberculosis Strains 
MDMs were infected with Mtb (HN878) at an MOI of 1. Host/ Mtb RNA and DNA was extracted at 0h, 4h, 12h 
and 24h utilising an optimised differential lysis and centrifugation protocol described below. Host cell nuclei 
were extracted and fixed at 0h and 4h post-infection for downstream ChIP-seq. 
5.2.4 Nucleic Acid Extraction, Nuclei Preparation and Sequencing 
Infected MDMs were differentially lysed in GTC buffer (5M guanidinium thiocyanate, 0.5% (w/v) sodium-N-
lauryl sarcosine, 25mM tri-sodium citrate, 0.1M β-mercaptoethanol and 0.5% Tween80) for 5 min. The cell 
lysate was removed to a new Eppendorf tube. The lysate was then centrifuged at max speed for 3 min at RT 
to pellet out the infectious bacilli. The supernatant, containing host nucleic acid was removed to a new 
Eppendorf tube and stabilised using TRIzol (ThermoScientific). The mycobacterial pellet was sheared in TRIzol 
using the FastPrep-24 (MP Biomedicals) bead beater and BeadBug Eppendorf Tubes (Sigma). Mtb RNA, host 
RNA and DNA were then purified using the standard TRIzol protocol. Quantification of the RNA extracte d was 
approximated using the Nanodrop (Thermoscientific). The RNA quality was assessed using the Bioanalyzer 
(Agilent). Samples were sequenced by our collaborators at the Institute of Bioengineering, Moscow, Russian 
Federation using an Illumina NextSeq 500. 
5.2.5 Bioinformatic Analysis 
Bioinformatic analysis (Fig. 35) of sequence data was achieved using FastQC (version 0.11.8), HISAT2, HTSeq-
count tool (version 0.11.2) with reference to the annotated human genome annotations downloaded from 
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GENCODE (Comprehensive gene annotation, Release 30 (GRCh38.p12)). Normalized counts were obtained by 
the DESeq2 R package and the statistics and plots were generated using custom R scripts.  
 
 
Figure 35: Schematic representation of the RNA-seq bioinformatic-pipeline used for the assessment of 





Optimal high throughput generation of MDMs can be achieved via negative immunomagnetic separation of 
monocytes and subsequent culture in media supplemented with serum 
The generation of MDMs can be affected by the isolation method as well as by variation in the culture medium 
used. In this study, we initially assessed the effect of immunomagnetic separation (negative and positive 
selection) vs. plastic adhesion for the purification of CD14+/CD16+ monocytes before differentiation to MDMs. 
Further, we assessed the role of media supplemented with serum (FCS or Hab) or without serum ( Ex vivo 
medium, Lonza) in the generation of the MDMs. Our data showed that adhere nce and the negative selection 
of monocytes elicited both similar yields and an estimated percentage adhesion of the cells after 7-days (Fig. 
37a-b).  The efficiency of differentiation was also calculated; the differentiation of monocytes isolated using 
negative selection was significantly more efficient than those isolated using adherence and positive selection 
(Fig. 37c).  
 
Figure 36: Monocytes isolated via negative selection and cultured under serum-free conditions produced 
phenotypically homogenous monocyte-derived macrophages. Monocytes isolated via plastic adherence or 
immunomagnetic separation in a range of culture media was observed to determine the degree of adherence 




The dual-RNA-seq methodology detailed in this study requires large amounts of primary human monocyte-
derived macrophages. Further, from the same donor, additional cells are required for downstream ChIP-seq 
experiments, thus increasing the number of MDM required after differentiation. Therefore, to differentiate 
enough of these cells, approximately 1x109 PBMCs are required per donor. As such, the high throughput 
method for the generation of MDMs required optimisation. Varying methods of MDM differentiation were 
investigated to assess macrophage adherence, yield and morphology. Monocytes were isolated by adherence 
or immune-magnetic separation via positive or negative selection. Additionally, the utilisation of human 
autologous serum, fetal calf serum and serum-free media supplemented with 50 ng/mL M-CSF was 
investigated. CD14+CD16+ monocytes, isolated via negative selection and differentiated in serum-free media, 
elicited macrophages which were morphologically homogenous and had the highest degree of confluence 




Figure 37: Monocyte-derived macrophages isolated via negative selection, and grown in the presence of 
FCS, had superior differentiation efficiency and had similar yields and degree of adherence to MDMs 
isolated via plastic adherence. Monocytes were isolated from PBMCs using adherence, negative selection or 
positive selection. Culture media with (RPMI + FCS or Hab) or without serum (Ex vivo media) was also assessed 
7-day post culture. To determine the optimum method A) percentage adhesion. B) The yield of MDMs 
recovered after 7-days and C) Differentiation efficiency was determined via the percentage number of MDMs 
harvested from the initial number of cells seeded. (*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001, one-




Additionally, by flow cytometry and available human antibodies, we analysed the efficiency by which the 
negative immunomagnetic separation protocol was able to isolate monocytes from PBMCs. PBMCs were 
isolated via traditional density centrifugation. Analysis of the cells showed that via negative selection, 
magnetic beads efficiently purified CD14+ monocytes from ~50% pre-isolation (Fig. 38a) to ~90% post-isolation 
(Fig. 38b). After 7-days of cell culture in differentiation media (RPMI + 10% FCS + 50 ng/mL),  the adherent 
monocyte-derived macrophages were harvested and analysed via flow cytometry (Fig. 38c). The cells were 
found to be CD3-, CD11b+, CD14- and HLA-DR+ in line with what is reported in the literature [279]. Further, the 
appearance of two distinct populations within the macrophage compartment (CD14+ and CD14-) implies a 
range of macrophage phenotypes generated after 7-days in the presence of M-CSF (Fig. 38c). In a recent study, 
it was reported that 50 ng/mL M-CSF can elicit two subsets of MDMs which differentiate into CD14 high and 
low populations and represent non-adherent and adherent MDM populations, respectively [279]. 
 
Figure 38: Negative-selection efficiently purifies monocytes from PBMCs and allows for the generation of 
phenotypically distinct macrophages. Monocytes and macrophages were analysed via Flow cytometry A) 
within PBMCs pre-negative selection, B) post-negative selection and C) after 7-day of culture in differentiation 
media. Monocytes (MoMs) = CD14+CD3-, monocyte-derived macrophages (MDMs) = CD14-CD3-CD11b+HLA-
DR+. (p=n/a, n=1) 
 
A brief explanation of the dual-GTC method used to isolate host and pathogen RNA 
This study employs differential lysis and centrifugation steps to differentiate between host and pathogen 
nucleic acid (Fig. 39). Adherent, differentiated MDMs (~2 x 106) are infected with the hypervirulent Beijing 
Mtb strain (HN878) at an MOI of 1. Host cells are then incubated to allow for uptake of bacilli. At each time 
point, the culture media is removed, and the cells are lysed using the GTC buffer. This lysis buffer selectively 
lyses host cells whilst leaving Mtb bacilli intact. The lysate is then centrifuged to pellet out the engulfed Mtb 
and the lysate, containing host RNA and DNA, is removed to a separate tube for downstream purification. The 
Mtb pellet is then sheared using silica beads to ensure adequate extraction of pathogen nucleic acids. After 
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both lysates have been extracted, they are purified using established protocols to provide host RNA and DNA 
as well as pathogen RNA. Further, additional MDMs were plated for ChIP-sequencing. 
 
 
Figure 39: General flow diagram of the dual-GTC methodology used in the optimisation of the dual RNA seq 
protocol. 
 
The dual-GTC method can successfully isolate host RNA as well as Mtb RNA 
The host and Mtb RNA acquired from using the dual-GTC method detailed above were assessed for quantity 
and quality (Fig. 40) for downstream sequencing. The host samples were found to be of good quantity (~5.4 
ug) and good quality (RIN = 8.6). Conversely, the Mtb RNA samples were of low quantity (~0.2 ug) and low 
quality as measured by a RIN value of 2.5. This finding was expected due to the low numbers of possible Mtb 




Figure 40: The dual RNA-seq methodology isolated host RNA of high quality/quantity, whilst Mtb RNA was 
found to be of low quality/quantity. RNA extracted from approximately 2 x 106 MDMs infected with Mtb an 
MOI of 1. RIN = RNA integrity number (*P ≤ 0.05, **P ≤ 0.01, students t-test, n=3/4). 
 
RIN values are not a good predictor of RNA quality for samples with very low RNA concentrations 
RIN values for the Mtb samples were deemed to be less than optimal for sequencing (RIN <7) (Fig. 40). To 
investigate this further, five independent experiments were pooled to assess the relationship between RNA 
quantity and RNA quality (RIN). From this analysis (Fig. 41), we observed a significant positive correlation 
between quantity and quality. As this study is limited by the number of host cells required for downstream 
analysis, increasing the number of Mtb by upscaling the MOI would negatively affect the viability of the MDMs. 
This is, therefore, an unfeasible alternative strategy for increasing the yield of Mtb RNA. From our data, it may 
be probable that the extracted Mtb RNA was near to, or below, the limit of detection for the Agilent 
Bioanalyzer 2100. However, we hypothesised that it may still be of sufficient quality for downstream 
sequencing applications. To test this hypothesis, we decided to sequence both sets of RNA (host and pathogen) 











































Figure 41: High RIN values are positivity correlated with increasing RNA concentration. RNA concentration 
and matched RIN data from five pooled independent experiments. (****P ≤ 0.0001, Pearson correlation, n=5). 
 
Commercially available leukopaks provide enough cells for downstream RNA-seq and ChIP-seq 
All donor blood samples purchased and utilised in the optimisation of this protocol were male and between 
the ages of 18-50-years old. The average age of 36 years was observed across the donor samples. Leukopaks 
are a blood product which is enriched for immune cells from peripheral blood. From our data, a single patient 
75 mL PBMC sample can contain approximately 1.5 x 109 PBMCs (Table. 6). Using negative selection, 
approximately 13.7 x 109 (~10 % of PBMCs) CD14+/CD16+ monocyte (MoMs) cells could be isolated via negative 
immunomagnetic separation. After 7-days in the differentiation culture medium, approximately 9 x 106   











Donor Age 36.17 9.13 0.9993 
PBMCs (x 109) 1.525 0.52 >0.9999 
MoMs (x 107) 13.68 4.77 0.7989 
MoMs (%) 10.10 4.98 0.9969 
MDMs (x 106) 9.79 2.71 0.9989 
MDMs (%) 7.73 2.60 0.9976 
 
RNA-seq data confirm the ability of the dual-GTC methodology to enrich Mtb transcripts and extract 
meaningful data from the host and pathogen 
The host and pathogen RNA were aligned to the homo sapien and Mtb genomes as detailed above. Within the 
human samples, approximately 18.0 – 26.0 M reads aligned uniquely to the reference genome, whilst a greater 
range was observed within the mycobacterial samples: viz, approximately 12.5 – 36.0 M reads (Fig. 42 and 43). 
Within the Mtb samples, a significant portion of the reads aligned uniquely to the Homo sapien genome. This 
observation is likely indicative of artefactual human RNA contamination within these samples during the 





Figure 42: RNA-seq data illustrated a sufficient number of unique reads for host and pathogen transcripts 
separately enriched using the dual-GTC methodology. RNA samples were aligned to the A) human and B) 
Mycobacterium tuberculosis genomes at 4h, 24h and 48h post-infection. Analysis performed and graphs 
created by Dr Ivan Antonov at the Institute of Bioengineering, Moscow, Russian Federation (p = n/a, n=1) 
 


























Figure 43: The dual-GTC methodology allows for the segregation of host- and pathogen-specific transcripts.  
RNA samples were purified from A) human primary MDMs and B) Mycobacterium tuberculosis genes at 4h, 
24h and 48h post-infection. Analysis performed and graphs created by Dr Yulia Medvedeva and Dr Ivan 
Antonov at the Institute of Bioengineering, Moscow, Russian Federation (p = n/a, n=1) 
 
Human and bacterial reads were aligned to known annotated gene entries in silico. On average, approximately 
81% of the human reads were aligned to annotated genes, whereas 67% of reads within the Mtb samples were 
aligned to known Mtb genes. Within the Mtb samples, ~5 million reads were aligned to the human genome 
(Fig. 43). This phenomenon is likely as a result of residual host RNA left behind during segregation of 
host/pathogen RNA via centrifugation. 


























Figure 44: mRNA and rRNA are the main transcripts identified for host and pathogen RNA, respectively.  RNA 
was isolated from A) human primary MDMs and B) internalised Mycobacterium tuberculosis at 4h, 24h and 
48h post-infection. Analysis was performed and graphs created by Dr Yulia Medvedeva and Dr Ivan Antonov 
at the Institute of Bioengineering, Moscow, Russian Federation (p = n/a, n=1) 
 
The gross majority of reads within the human samples aligned to protein-coding genes, followed by a small 
proportion of mitochondrial ribosomal RNA (Mt_rRNA) and long-non-coding RNA (lncRNA) (Fig. 44). Due to 
the low number of Mtb hypothesised to be phagocytosed by the MDMs, a bead abased rRNA clean-up of the 
rRNA was anticipated to have a catastrophic effect on the already-limited yield of coding and non-coding RNA. 
Thus, within the Mtb enriched samples, the greatest percentage of reads were identified as ribosomal RNA 
(rRNA) followed by protein-coding genes and then lncRNA. 
 
Table 7: Summary of Average RNA Sequence Data. 
 
 

























In summary, the RNA sequence data for the human samples were more than sufficient for statistical analysis 
and identification of important transcriptomic changes (Table. 7). Despite the technical and MOI-limiting 
phenomenon for the Mtb RNA samples, sufficient reads were also acquired for robust downstream statistical 
analysis. 
 
The dual-GTC method proved sequence data representative of Mtb and human genomes 
Figure 45 informs on the range of uniquely annotated reads acquired for the host and pathogen using this 
dual-RNA methodology. For the host samples, an average of 16135.75 genes aligned uniquely to the host 
reference genome, with an average number of ~3000 reads per gene (Fig 45a). This estimate is similar to the 
anticipated number of protein-coding genes in the human genome [280, 281]. Within the Mtb samples, an 
average of 4078 uniquely aligned genes was detected with an average number of approximately 2500 reads 
per gene (fig. 45b). Together, these indicate that that the dual-GTC mythology provides robust RNA which is 
representative of both the host as well as the pathogen. 
 
 
Figure 45: The total number of reads and the number of unique genes identified per timepoint in all samples. 
Read data and the number of genes which aligned uniquely for A) human MDM samples and B) Mtb samples 
at 4-, 24- and 48-hours post-infection. Analysis performed and graphs created by Dr Yulia Medvedeva and Dr 




Gene expression profiles are characteristic of Mtb infection 
To assess the final fidelity of the dual-GTC methodology, several marker genes were assessed from both the 
host and the pathogen sequence data. In human MDM Mtb infection, IL1α, IL1β, IL10, CCL1, CXCL8, TLR2, IRF7, 
CCL7, CXCL1, CXCL3, PTGS2 and IL12β were all found to be upregulated by Mtb infection (Fig. 46). Further, 




Figure 46: Normalised gene counts from primary MDMs (Blue) and internalised mycobacteria (green) post-
infection illustrate the success of segregation and analysis of host/pathogen transcriptomic profiles. Data 
extrapolated from RNA-seq data for a single pilot donor. Samples sequenced by the Institute of 
Bioengineering, Moscow, Russian Federation (p = n/a, n=1) 
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5.4  Discussion 
The ability to elucidate and correlate transcriptional and epigenetic changes, that occur within both the 
pathogen and the host at the same time point, has two primary benefits. Firstly, this approach can add to the 
knowledge of TB pathogenesis, and secondly, this method may highlight novel targets for therapeutic 
intervention. The dual RNA-seq method described in this study has several advantages; namely, (i) it allows 
for the bulk generation of MDMs in quantities sufficient for a longitudinal assessment of dual RNA-seq, ChIP-
seq and BS-Seq Data on a per human donor basis; (ii) it allows for the cost-effective enrichment of 
phagocytosed Mtb bacilli without the need for FACs sorting such as previously shown in other studies [249, 
282]; (iii) it only requires basic laboratory equipment; and (iv) serves as a good starting point before validatory 
PCR and more in-depth single-cell RNA-seq studies. 
To date, few in vivo or ex vivo mycobacterial dual RNA-seq studies have been published. This phenomenon is 
largely due to the technical difficulties inherent with this approach. For example, increased depth, RNA yield 
differences between eukaryotic cells and rRNA depletion are some of the obstacles that need to be optimised 
[228]. To by-pass these issues, several studies have explored the transcriptional changes in macrophage -like 
cells lines  [283, 284]. These studies have informed on the role of nutrient dynamics and altered metabolism 
of mycobacteria in vitro. In the ex vivo leprosy model, dual RNA-seq has been used to identify specific gene 
signatures which result in different clinical manifestations, highlighting the importance of understanding site-
specific inflammation caused by pathogenic mycobacteria and disease progression [285]. Very recently, dual 
RNA-seq has been used in in vivo murine-Mtb infection models to assess the host response to Mtb and nutrient 
immunity [249]. In vivo human-Mtb dual RNA-seq infection studies, in combination with epigenetic sequencing 
experiments, are still technically unfeasible due to the number of human immune cells and engulfed Mtb 
required. Our study attempts to circumvent this obstacle though the examination of ex vivo primary MDMs. 
However, this protocol is limited by the large amount of terminally differentiated MDMs required to acquire 
adequate DNA, RNA and host nuclei for downstream sequencing applications. From our data, we observed 
that approximately 10% of donor PBMCs were monocytes and that post-differentiation, ~8% of monocytes 
could be differentiated to macrophages (Table. 6). These percentages are similar to previously published 
studies [286]. Further, whilst it is assumed that the large majority of Mtb are phagocytosed by the MDMs, 
some bacilli may not be internalised or washed away during the processing steps before the lysis of the MDMs. 
This phenomenon may introduce sequence noise in the analysis, as these bacilli would have likely experienced 
other non-immune linked stressors. Additional optimisation has shown that, at an MOI of 5, approximately 
20% of cultured macrophages are infected with Mtb after four hours of uptake (data not shown). Higher MOI’s 
may infect more macrophages, however, this is at the cost of macrophage viability and a compromised host 
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transcriptome. For this reason, we chose to use a lower MOI of 1 within this study. Whilst conserving 
macrophage viability, a low MOI creates other experimental issues which need to be overcome.  
In previous bulk RNA sequencing studies which have investigated Mtb transcriptomic profiles, Mtb cultures 
grow to the mid-log phase prior to lysis and nucleic acid extraction [284, 287]. This constitutes a culture 
containing hundreds of millions of colony-forming units (CFUs) and a surplus of mycobacterial RNA for 
downstream sequencing. This contrasts with our study, where a theoretical maximum number of ~2 million 
Mtb CFU could potentially be sequenced. However, this is under the improbable assumption that 100% of all 
engulfed Mtb are phagocytosed. This observation is emphasised by the disparity observed between the total 
host RNA and pathogen RNA yield (Fig. 40).  Similar findings were observed in the monocyte-like THP-1 BCG 
infection model. In that study, the authors found that mycobacterial RNA was underrepresented in their 
samples approximately 1000-fold relative to THP-1 RNA [284].  Further, we show that a significant number of 
reads in the bacterial samples contain transcripts which align to the human genome, constituting sequence 
noise and in the pathogen samples. Despite using reagents specifically designed for the analysis of low yield 
prokaryotic RNA yields, the analysis of mycobacterial RNA quality via the RNA integrity number (RIN) becomes 
progressively less robust with decreasing RNA quantity in the sample (Fig. 41). This observation is further 
emphasised by the validatory sequence data which could be extrapolated from the “low quality” Mtb RNA 
samples (Fig. 46). Together, these lines of data imply that whilst the Mtb RNA is of low yield and seems to be 
below the limit of detection for the RNA quality analysis, the dual-GTC method and subsequent in silico analysis 
were successfully able to enrich Mtb transcripts and annotate sufficient mycobacterial reads from these 
separated samples for robust statistical analysis. 
In this study, the dual RNA-seq methodology provided a mean total of 25.5M host and 57.4M Mtb reads; of 
which 22M and 25.5M mapped uniquely to the human and Mtb genomes, respectively. (Table 7 and Fig. 42). 
Within the Mtb samples, 9.4M reads aligned to the human genome (artefactual contamination) and contained 
~84.7% rRNA which is similar to that of other dual-RNA-seq Mtb studies [249]. Correcting for this, 
approximately 2.8M unique Mtb reads (3.5 - 5.7 %) were found to available for downstream analysis (Table 
7). This is in line with early bacterial sequencing studies which postulated that a minimum of 2-5 million 
sequence reads are required comprehensive transcriptomic coverage [231-233]. Whilst the reads acquired 
using this method in its current form are adequate, reducing the depth required during sequencing is 
economically beneficial. There are several aspects of this methodology which we are still working to improve 
upon. For instance, the contamination of host nucleic acid within our pathogen samples significantly increases 
the sequencing depth to which we must go to to achieve an adequate amount of Mtb-specific reads. Additional 
washing steps of the mycobacterial pellet may be beneficial in removing contaminating host nucleic acid.  
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In the following study, we describe a high-throughput method for the generation of MDMs, their subsequent 
infection with Mtb, and the extraction of host RNA, DNA and nuclei as well as internalised pathogenic RNA 
within those same macrophages on a per donor basis without the need for fluorescent cell sorting . This 
optimised enrichment methodology, in combination with additional epigenetic sequencing experiments, will 
allow for the identification and targeting of novel gene lncRNA interactions important to understanding the 
biology of TB pathogenesis. Such hypothesis-generating data will allow for the targeted investigation of 
subsequent follow-up epigenetic studies. 
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Conclusions and Future Work 
 
TB is an ancient disease which has successfully affected humanity for millennia. Further, the modern 
emergence of multidrug resistance has highlighted the need for new anti-TB therapeutics. Understanding the 
biology of Mtb, particularly the homeostatic regulation of its cell wall, are crucial for the development of novel 
compounds. In this study, I have assessed the immunological effects of the Mtb deficient for two cell wall 
hydrolytic enzymes, Ami1 and Ami4, in the aim of both understanding the consequences of these deletions in 
the context of the host immune response, as well as potentially assessing the potential of these genes for 
novel drug development. In non-pathogenic mycobacterial species, amidase deficiency has been shown to 
confer deleterious cell wall remodelling phenomena such as atypical septation and the formation of long 
strings of filamentous mycobacterial. Further, these mutants have been shown to elicit heightened sensitivity 
to existing first-line anti-TB drugs. In this study, we show that amidase deficiency in Mtb alters the host 
immune response during acute infection, however, the single deletion of Ami1 or Ami4 was unable to elicit 
the clearance of Mtb in the acute or chronic phase of the infection relative to wild-type controls. Further, 
amidases probably act in synergy with other cell wall remodelling enzymes, thus, any sensitivity to antibiotic 
or immune pressures may be compensated for by additional genes. Interestingly we also found that the Δami1 
mutant was sensitive to meropenem in vitro and tolerant to isoniazid in vivo. In contrast, Δami4 is dispensable 
for the host immune repose and antibiotic sensitivity. Taking this project further, we plan to further explore 
the phenomenon of antibiotic sensitivity and the host immune response in Ami1 deficient Mtb infection. This 
will be done both in vitro using NOD1/2 cell lines and culture supernatants from Δami1 axenic cultures relative 
to complemented and wild type strains. Further, we plan to elaborate on our in vivo antibiotic data by 
examining the relationship of BCG vaccination and subsequent infection with Δami1 Mtb. 
Mtb infection and the subsequent host immune response involve complex interactions at the transcriptomic 
and epigenetic levels. There is increasing evidence for the ability of Mtb to subvert the host immune response 
through numerous strategies, such as DNA methylation, histone modification and the induction of ncRNAs. 
Understanding these changing landscapes during infection is key to adding to the knowledge of TB 
pathogenesis and for the elucidation of novel targets for anti-TB drug design. In this study, I report an 
optimised protocol for the high throughput generation of MDMs as well as a method for the enrichment of 
Mtb transcripts from bacilli engulfed by the primary MDMs. Therefore, this protocol will allow for the in-depth 
analysis of the host-pathogen interactions in response to epigenetic changes during infection. Not only will 
this add to the knowledge of TB, but it can also be applied to other Mtb mutant models of  infection to elucidate 
novel drug targets. Further, this protocol can be readily adapted to other bacterial species which possess a 
thick outer capsule or cell wall.  
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Utilising this protocol, the next steps in the project will be the assessment of primary  macrophages infected 
with Mtb deficient for Rv2966c, a 5-methylcytosine-specific DNA methyltransferase, which is secreted by Mtb 
and is translocated to the host nucleus, as well as Rv1988, an Mtb methyltransferase. Both Mtb proteins have 
been shown to play a role in the reprogramming of the host immune system to confer persistence within the 
host. Using dual RNA-seq in combination with ChIP-seq and BS-seq we hope to reconstruct the host-pathogen 





Supplementary Table 1: List of primers used in the construction of amidase deficient M. tuberculosis strains. 
 
*red: restriction endonuclease site 
 
Supplementary Table 2: Bacterial strains and plasmids created/used in this study 
Strain  Genotype  Reference  
H37RvS Virulent laboratory isolate ATCC 25618 Laboratory Stock 
H37∆ami1S A derivative of H37RvS carrying an unmarked, in-
frame deletion in ami1, containing 96 bp of the 5’ 
and 78 bp 3’ regions, lacking 551 bp of the ami1 
gene  
This study 
H37∆ami4S A derivative of H37RvS carrying an unmarked, in-
frame deletion in ami4, containing 39 bp of the 5’ 






p2H37ΔAmi1G17 A derivative of p2NIL carrying a truncated 
derivative of the H37RvS ami1 gene and the lacZ 
and sacB genes from pGOAL17, KanR 
This study 
 
Primer Sequence Amplicon 
H37ami1KOUSF GTGAAGCTTGCCGCATTACCAGCTATGAC 1577 bp amplicon the 5’ region of 
the ami1 gene and 96 bp of the 
ami1 gene 
H37ami1KOUSR GTGTCTAGAGTCGATGAAGACGACCATGC 
H37ami1KODSF GTGTCTAGACGAGGGCAGGCAAAAATAC 1579 bp amplicon the 3’ region of 
the ami1 gene including 78 bp of 
the ami1 gene H37ami1KODSR GTGGGTACCGCCATCAACCTCCAGTAGACA 
H37ami4KOUSF GTGAAGCTTACCGGCAAGACTGCATAAC 1557 bp amplicon the 5’ region of 
the ami4 gene and 39 bp of the 
ami4 gene 
H37ami4KOUSR GTGTCTAGACACCTCCTCGAGCCAAATC 
H37ami4KODSF GTGTCTAGACGAGCTCGGCAATAAGGTC 1530 bp amplicon the 3’ region of 
the ami1 gene including 82 bp of 
the ami1 gene H37ami4KODSR GTGGGTACCCGATCCGCTGTGACAATAGA 
H37ami1pMVF GCGCGCGCAAGCTTGCCATCTTCGTCACCTGC 1126 bp ami1 amplicon including 
400 bp upstream the ami1 start 
codon H37ami1pMVR GCCGCCGCGTTAACCTAACGCGCCTGGCCCTG 
H37ami4pMVF GCGCGCGCAAGCTTCGGCCTCGCCCGTCCGAC 1311 bp ami4 amplicon including 
400 bp upstream the ami4 start 




p2H37ΔAmi4G17 A derivative of p2NIL carrying a truncated 
derivative of the H37RvS ami4 gene and the lacZ 
and sacB genes from pGOAL17, KanR 
This study 
KanR: Kanamycin Resistance, HygR: Hygromycin Resistance 
 
 
Construction of amidase deficient strains in M. tuberculosis 
To generate the ami1 and ami4 deletion mutants, H37ami1KO and H37ami4KO primers listed in Table S1 were 
designed to amplify the upstream and downstream regions of homology for both the ami1 and ami4 gene. 
The resulting upstream and downstream products were fused together to yield ami1 and ami4 in-frame 
deletion alleles. These were then cloned into p2NIL [288] respectively, followed by insertion of a marker 
cassette from pGOAL17 [288] into the resulting vectors to create the final amidase deletion constructs, 
p2H37ΔAmi1G17 and p2H37ΔAmi4G17. These suicide vectors were then transformed into electro-competent 
M. tuberculosis H37RvS which were then subjected to two-step allelic exchange mutagenesis yielding the 
Δami1 and Δami4 mutant strains. The resulting mutants were screened by PCR using the H37ami1pMV and 














Supplementary Figure 3: No difference in growth was observed per strain used in this study. This was 
assessed Dr Sibusiso Senzani and Dr Melissa Dalcina Chengalroyen, DST/NRF Centre of Excellence for 
Biomedical TB Research, Faculty of Health Sciences, University of the Witwatersrand, National Health 




Supplementary Figure 4:  Plot of power (1-β error probability) vs. total sample size for determination of 
appropriate numbers of experimental mice per group. A minimum of 9 samples (3 mice per group) was 
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